Official Title:  A Phase II trial to improve outcomes in patients with resected 
pancreatic  adenocarcinoma at high risk for recurrence using epi[INVESTIGATOR_756961]: February 18, 2022  
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]  
 
 SKCCC J12138 
IND 117362 
  
T i t l e :  A  P h a s e  I I  t r i a l  t o  i m p r o v e  o u t c o m e s  i n  p a t i e n t s  w i t h  r e sected pancreatic 
adenocarcinoma at high risk for recurrence using epi[INVESTIGATOR_756962]:       Nilofer Azad, MD  
 
Study drug provided by:      [CONTACT_757014] :    Johns Hopkins Sidney Kimmel Comprehensive 
Cancer Center  
 
Principal Investigator :   
    [INVESTIGATOR_307987], MD  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 
 
 
 
 
 
Research Nurse:    Sheila Linden, RN  
        
       
      
 
Statisticians:      E l i z a b e t h  S u g a r ,  P h D   
  
  
 
 
 
 
  

    SKCCC J12138  
IND 117362  
  Confidential    
  
2 
Version 11.0 / February 18, 2022  Participating Sites  
Peter J. O’Dwyer, M.D.   
The Hospi[INVESTIGATOR_756963] K. Monga, M.D. 
Allegheny General Hospi[INVESTIGATOR_756964], except to 
the extent necessary to obtain informed cons ent, may not be disclosed to another party 
unless law or regulations require such disclosure.  Persons to whom the information is 
disclosed must be informed that the inform ation is confidential and may not be further 
disclosed by [CONTACT_476].  
  
    
 
  

    SKCCC J12138  
IND 117362  
  Confidential    
  
3 
Version 11.0 / February 18, 2022  PRINCIPAL INVESTIGATOR [INVESTIGATOR_202105]/Sponsor Approval:  
This clinical study protocol has  been reviewed and approved by [CONTACT_757015]:  
 Nilofer Azad, MD                                                                                                                 
  Print Name    [CONTACT_757046], Johns Hopkins 
                                                                                                                                                n 
 Title, Medical Institution             Date (DD MMM YYYY)    
 
Investigator’s Signature:  
I have fully discussed the objec tives of this study and the con tents of this protocol with the 
Sponsor’s representative.  
I understand that information co ntained in or pe rtaining to thi s protocol is confidential and 
should not be disclosed, other than to those directly involved in the execution or the ethical 
review of the study, without writte n authorization from the Spo nsor. It is, however, 
permissible to provide informati on to a subject in order to obt ain consent.  
I agree to conduct this study acco rding to this protocol and to  comply with its requirements, 
subject to ethical and safety c onsiderations and guidelines, an d to conduct the study in 
accordance with the Declaration of  Helsinki, International Conf erence on Harmonization 
guidelines on Good Clinical Pract ice (ICH E6), and applicable r egional regulatory 
requirements.  
I agree to make available to Spons or personnel, their represent atives and relevant regulatory 
authorities, my subjects’ study r ecords in order to verify the data that I have e ntered into the 
case report forms. I am aware of  my responsibilities as a Princ ipal Investigator as provided 
by [CONTACT_1034].  
I understand that the Sponsor may decide to suspend or prematur ely terminate the study at 
any time for whatever reason; such a decision will be communica ted to me in writing. 
Conversely, should I decide to withdraw from execution of the s tudy, I will communicate 
my intention immediately i n writing to the Sponsor.  
  
    SKCCC J12138  
IND 117362  
  Confidential    
  
4 
Version 11.0 / February 18, 2022  --------------- --------------   --------------- ------------- ------------           
Print Name   [INVESTIGATOR_7496]    
------------------ -------    ------ --------------- ------------ ---------- 
  Title   Date (DD MMM YYYY)    
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
    SKCCC J12138  
IND 117362  
  Confidential    
  
5 
Version 11.0 / February 18, 2022  Table of Content  
1 Protocol Synopsis ........................................... ............................................................... ........ 9 
1.1 Description ............................................... ............................................................... ........ 9 
1.2 Schema .................................................... ............................................................... ....... 12 
2 Schedule of Study Assessments ............................... ........................................................... 13  
2.1 Schedule during Initial P hase – Arm A & Arm B ............. ....................................... 13  
2.2 Schedule during Follow Up – All Subjects* ................. .............................................. 17  
3 Background and Rationale .................................... ............................................................. 1 8 
3.1 Adenocarcinoma of the pancreas ............................ .................................................... 18  
3.2 Epi[INVESTIGATOR_756965] ......................... ..................................................... 20  
3.3 5-Azacitidine ............................................. ............................................................... ..... 20 
3.3.1 Indication and Usage .................................... ........................................................... 23  
3.3.2 Adverse Events .......................................... .............................................................. 23 
3.4 Rationale for Treatment in this Setting ................... .................................................. 24  
3.5 Correlative Studies ....................................... ............................................................... . 25 
4 Study Objectives and Endpoints .............................. .......................................................... 26  
4.1 Objectives ................................................ ............................................................... ....... 26 
4.2 Endpoints ................................................. ............................................................... ...... 26 
5 Investigational Plan ........................................ ............................................................... ...... 27 
5.1 Overall design ............................................ ............................................................... .... 27 
5.1.1 5-Azacitidine Description ............................... ........................................................ 27  
5.2 Screening and Eligibility ................................. ............................................................ 30  
5.2.1 Inclusion Criteria ...................................... ...............................................................  3 0 
5.2.2 Exclusion criteria ...................................... .............................................................. 31 
5.2.3 Inclusion of Women and Minorities ....................... ................................................ 32  
5.2.4 Patient Recruitment ..................................... ............................................................ 32  
5.2.5 Protocol and Drug Administration ........................ .................................................. 32  
5.2.6 Multicenter Guidelines .................................. .......................................................... 32  
5.2.7 Patient Registration .................................... ............................................................. 3 3 
5.2.8 Randomization ........................................... ............................................................. 3 4 
    SKCCC J12138  
IND 117362  
  Confidential    
  
6 
Version 11.0 / February 18, [ADDRESS_1036297] of administration ............................... ........................................................ 35  
5.3 Visit Schedule, Assessments , and Dose Modifications ....... ....................................... 35  
5.3.1 Screening and Pre-Study Assessments ..................... ............................................... 36  
5.3.2 Initial Phase: Assessments , Dose Modifications, and Termi nation ........................ 36  
5.4 Discontinuation of Treatment: Arm A ....................... ................................................ 39  
5.4.1 End of Treatment ........................................ ............................................................. 4 0 
5.5 Follow-up Phase Both Arms ................................. ....................................................... 40  
5.6 Concomitant Therapy ....................................... ........................................................... 41  
5.6.1 Recommended Concomitant Therapy ......................... ............................................ 41  
5.6.2 Prohibited Concomitant Therapy .......................... .................................................. 42  
5.7 Treatment adherence ....................................... ............................................................ 42  
6 Adverse events .............................................. ............................................................... ........ 42 
6.1 Definitions Adverse Ev ent (AE) Definition ................. ............................................... 42  
6.1.1 Serious Adverse Event (SAE) Definition .................. ............................................. [ADDRESS_1036298] Information: ................ ............................................. 46  
6.3 Investigator Reporting Responsibilities ................... .................................................. 46  
6.3.1 Expedited reporting by [CONTACT_757016] .......... ............................................ 46  
6.3.2 Report of Adverse Events to the Institutional Review Boar d ................................. 46  
6.3.3 Investigator Reporting to the FDA ....................... ................................................... 46  
6.4 Adverse event updates/IND safety reports .................. .............................................. 47  
7 Radiologic Evaluation ....................................... ............................................................... ... 47 
7.1 Baseline imaging assessments .............................. ....................................................... 47  
7.2 Definitions of Measurable and Non-Measurable Disease ...... ................................... 48  
7.3 Guidelines for Evaluation  of Measurable Disease ........... ......................................... 49  
7.3.1 Measurement Methods ..................................... ....................................................... 49  
7.3.2 Acceptable Imaging Modalities for Measurable Disease .... .................................... 49  
    SKCCC J12138  
IND 117362  
  Confidential    
  
7 
Version 11.0 / February 18, [ADDRESS_1036299] ................................... ......................................................... 50  
7.3.5 Response Criteria during Follow-up Phase ................ ............................................. 50  
7.3.6 Overall Objective Status  during Follow-up Phase ......... ......................................... 51  
8 Correlative Studies ......................................... ............................................................... ...... 53 
8.1 Plasma/Serum Samples ...................................... .......................................................... 53  
8.2 Tumor Biopsies ............................................ ............................................................... .. 54 
8.2.1 Specimen Collection and Handling ........................ ................................................. 55  
9 Protocol Amendments/Deviations .............................. ........................................................ 56  
9.1 Protocol Amendments ....................................... ........................................................... 56  
9.2 Protocol Deviations ....................................... ...............................................................  5 6 
10 Data Management ............................................ ............................................................... .. 56 
10.1 Data Collection .......................................... ............................................................... .. 56 
10.2 Analyses and Reporting ................................... .......................................................... 56  
10.3 Clinical Trial Monitoring ................................ .......................................................... 57  
10.4 Investigator Responsibilities ............................ ......................................................... 57  
10.5 Safety Meetings .......................................... ............................................................... . 58 
11 Biostatistical Analysis .................................... ............................................................... .... 58 
11.1 Study Design/Endpoints ................................... ......................................................... 58  
11.2 Study Populations ........................................ .............................................................. 58 
11.2.1 Efficacy Evaluable Population .......................... .................................................... 58  
11.2.2 Methylation Analysis Population ........................ .................................................. 58  
11.3 Statistical Methodology .................................. ........................................................... 59  
11.3.1 Efficacy Analyses ...................................... ............................................................ 59  
11.3.2 Methylation Analyses ................................... ......................................................... 59  
11.3.3 Quality of life analysis ............................... ........................................................... 59  
11.3.4 Sample Size ............................................ ...............................................................  6 0 
11.3.5 Safety Monitoring ...................................... ........................................................... 60  
11.3.6 Futility Analysis ...................................... .............................................................. 61 
12 Regulatory Considerations .................................. ............................................................. 6 2 
    SKCCC J12138  
IND 117362  
  Confidential    
  
8 
Version 11.0 / February 18, [ADDRESS_1036300]/ Ethics Committee approval ..... .................................. [ADDRESS_1036301] Confidentiality .................................. ............................................................ 63  
12.4 Study Records Requirements ............................... ..................................................... 63  
12.5 Premature Discontinuation of Study ....................... ................................................. 63  
13 References ................................................. ............................................................... .......... 64  
14 Appendices ................................................. ............................................................... ......... 68 
Appendix A: ECOG Performance Status Scale ..................... ......................................... 68  
Appendix B: Medication Diary .................................. ....................................................... 69  
Appendix C: Recommendations for Management of Treatment-Induced  Diarrhea (for 
CC-486) ....................................................... ............................................................... ...... 71 
Appendix D: FACT – Hep (Version 4) ............................ ................................................. 72  
 
 
     
    SKCCC J12138  
IND 117362  
  Confidential    
  
9 
Version 11.0 / February 18, 2022  1 Protocol Synopsis  
1.1 Description  
PROTOCOL TITLE:  A phase II trial to improve outcomes in patients with resecte d
pancreatic adenocarcinoma at hi gh risk for recurrence using epi [INVESTIGATOR_756966]:    
INDICATION:  Cancer Therapy  
STUDY PHASE:  Phase II  
BACKGROUND AND RATIONALE:     
DNA methylation is often abnormal in cancer cells and can lead to the inactivation of tumor 
suppressor genes.  Hypomethylatin g agents, such as 5-azacitidin e, have been shown to 
reverse DNA hypermethylation and allow for reactivation of tumo r suppressor genes and 
ultimately lead to cancer cell death.  These agents are current l y  t h e  s t a n d a r d  o f  c a r e  i n  
myelodysplasia and have also shown some efficacy in early phase  trials for solid tumors.  In 
pancreatic cancer cell lines, pro moter regions of several tumor  suppressor genes have been 
demonstrated to be abnormally hypermethylated.  The addition of  hypomethylating agents 
has restored the expression of these genes and has decreased tu mor growth.  While most of 
the trials have used the subcutaneous delivery of azacitidine, the oral formulation, CC-486, 
is currently being studied in a phase I trial for MDS/AML and h as been shown to be 
bioavailable, well-tolerated, and produce similar clinical resp onses as the subcutaneous 
version.  
  
Pancreatic adenocarcinoma is a very deadly disease, with only 2 0% of patients being 
candidates for possible curative surgery at presentation.  Howe ver, th e m ajority of  these 
patients will recur.  Patients that are node positive or margin  positive at the time of resection 
have a greater than 90% chance of recurrence and death from dis ease.  After surgery and 
adjuvant therapy, patients are monitored with CT scans and CA 1 9-9 levels.  In some 
patients, CA 19-9 levels rise before visible disease progressio n, suggesting micro-metastatic 
disease.  After completing adjuva nt chemotherapy, further chemo therapy is typi[INVESTIGATOR_756967]; however a therapy 
that is well-tolerated would be ideal in this setting.  The goa l of this trial is to demonstrate 
that CC-486 is well tolerated and effective when given after ad juvant therapy in patients 
with high risk disease (rising CA 19-9, node positive disease, or margin positive disease) by 
[CONTACT_757017], increasing respo nse rates to eventual 
chemotherapy, and increas ing overall survival.  
    SKCCC J12138  
IND 117362  
  Confidential    
  
10 
Version 11.0 / February 18, 2022  STUDY OBJECTIVES:  
Primary objective:  
To improve progression free survival in high risk patients with  resected pancreatic 
adenocarcinoma who have node positive disease, margin positive disease, and/or elevation 
in CA 19-9 treated with CC-486 as compared to observation after  completion of adjuvant 
therapy.  
 
Secondary objectives:  
1) To improve response rates to first-line chemotherapy (partial a nd complete response)
after recurrence in patients tr eated with CC-486 after completi ng adjuvant therapy.  
2) To improve overall survival in p atients with resected pancreati c adenocarcinoma
treated with CC-486.  
3) To evaluate resected pancreatic cancer tissue and biopsies at t ime of recurrence fo r
epi[INVESTIGATOR_756968]-
486.  
4) To evaluate resected pancreatic  cancer tissue and blood samples  to identify predictive
signatures of possible recurren ce and the benefit of hypomethyl ating therapy.  
5) To evaluate quality of life dur ing CC-486 using the FACIT-Hep q uestionnaire 
STUDY ENDPOINTS:  
Primary endpoint:  
The primary endpoint of the trial is to demonstrate an increase  in the progression free survival,
PFS, in resected pancreatic cancer  patients treated with CC-486 .  
  
Secondary endpoints:   
1) Response rate (including partia l and complete response) to firs t-line chemotherapy
when given after visible disease recurrence in patients primed with CC-486 compare d
to observation.  
2) Overall survival  
3) Decreased methylation in candidate genes in the research biopsi es as compared to the
original resected specimens  in patients treated with CC-486.  
4) Change in quality of life as de termined by [CONTACT_720361]-HEp scores  
    SKCCC J12138  
IND 117362  
  Confidential    
  
11 
Version 11.0 / February 18, 2022  STUDY DESIGN:  
This trial is for patients with r esected pancreatic adenocarcin oma who have concluded 
adjuvant therapy or were deemed unable to receive adjuvant ther apy with an elevated CA 
19-9 or node positive or margin positive disease.  CA 19-9 elev ation is defined as two levels 
> the institutional upper limit of  normal (ULN) taken at least 2 weeks apart.  These levels 
should be measured after adjuvant  therapy has concluded or upon  the decision that adjuvant 
therapy will not be offered. Patients will be randomized to one  of two arms.  Subjects 
enrolled due to node + disease or R1 resection must be able to undergo randomization within 
[ADDRESS_1036302] scans (or MRI, if clinically indicated) will be done eve ry three months. When 
patients have visible disease recurrence on imaging, CC-[ADDRESS_1036303]-line chemotherapy.  
  
STUDY DURATION:    
Assuming the maximum accrual with a goal 
of 2-3 subjects accrued per month, we estimate enrollment duration of 24 months 
with an additional 12 months for follow-up 
with concurrent data analysis and manuscript 
preparation.  TOTAL SAMPLE SIZE:  
Maximum 60 patients, with 30 patients in each 
of the two arms.    
DRUG SUPPLIES:  
For study participants, Celgene Corporation will provide CC-486   
DOSING REGIMEN:  
Treatment 
Arm  DRUG  DOSE  FREQUENCY # of CYCLES  Route  
  
A  
  CC-486  300 mg  
total, three  
100 mg  
tablets  Daily, Days 1-
21, Q28 Day 
cycles  12 cycles an d
then follow-up  Oral  
B  Observation  N/A  N/A  12 cycles. 
Follow-up 1 
will be collected 
3 months after 
Cycle 10.  N/A  
    SKCCC J12138  
IND 117362  
  Confidential    
  
12 
Version 11.0 / February 18, 2022  1.2 Schema  
  
  
  
  
  
  
    
  

    
SKCCC J12138  
      IND 117362 
    Confidential    
13 
Version 10.0 / July 2, 2020   2 Schedule of Study Assessments  
2.1 Schedule during Initial P hase – Arm A & Arm B  
For Arm A ±3 day window for study assessment s and ± 2 weeks for Tumor Assessments.   
For Arm B, schedule variations are permitted for Tumor Assessments and CA19-9 collection  
Procedure  Screening   Cycle 1  Cycles 2, 3, 5, 6, 
8, 9, 11 and 12  Cycles 4, 
7 and 10  Safety 
Assessment Upon Visible 
Disease 
Progression  ≤28 days 
prior to C1D1 (Day 1) (Day 1) (Day 1) [ADDRESS_1036304] 
d/c CC-486  
 Arm A Arm B Arm A Arm A Arm B Arm A Arm A & B 
CC-486 dosing (D1-
21)20   X    X  X       
Prior medications & anti-cancer Therapi[INVESTIGATOR_014] 
 X               
Physical examination   X X1    X  X    X  X7 
Vital signs   X  X1    X  X    X  X7 
Weight  X  X1    X  X    X  X7 
ECOG performance 
status9 X  X1    X  X    X  X7 
Tumor assessment including CT or MRI chest/abd/pelvis
10 X        X11 X6, 11, 15    X7 
CBC with differential   X  X1    X  X    X  X7 
    
SKCCC J12138  
      IND 117362 
    Confidential    
14 
Version 10.0 / July 2, 2020  Procedure  Screening   Cycle 1  Cycles 2, 3, 5, 6, 
8, 9, 11 and 12  Cycles 4, 
7 and 10  Safety 
Assessment Upon Visible 
Disease 
Progression  ≤28 days 
prior to C1D1 (Day 1) (Day 1) (Day 1) [ADDRESS_1036305] 
d/c CC-486  
 Arm A Arm B Arm A Arm A Arm B Arm A Arm A & B 
Serum chemistry and 
hepatic panel  X  X1    X  X    X  X7 
PT/PTT  X              X7 
CA 19-[ADDRESS_1036306] adverse 
events/symptoms17 X  X1    X  X    X  X 
Collect remaining pi[INVESTIGATOR_756969]
[ADDRESS_1036307] concomitant therapi[INVESTIGATOR_014]/procedures  X
  X1    X  X    X  X 
Archival Tissue16, 19 X              
Quality of Life   X  X1 X1, 5    X X5 X14 X7 
 
    
SKCCC J12138  
      IND 117362 
    Confidential    
15 
Version 10.0 / July 2, 2020  In order to minimize the need for research-only in-person vis its, telemedicine visits may be substituted for in person clinical  trial visits or portions of 
clinical trial visits where determined to be appropriate and wh ere determined by [CONTACT_757018]. Prior to initiating 
telemedicine for study visits the study team will explain to th e participant, what a telemedicine visit entails and confirm tha t the study participant is in 
agreement and able to proceed with this method. Telemedicine a cknowledgement will be obtained in accordance with the Guidance f or Use of 
Telemedicine in Research. In the event telemedicine is not deem ed feasible, the study visit will proceed as an in-person visit.  Telemedicine visits will be 
conducted using HIPAA compliant method approved by [CONTACT_12805].  
 
1       If study assessment assessed within 7 days of Cycle 1, Da y 1, they do not need to be repeated.  
2       Correlative blood sampling is  optional for patients in Ar m B except for at screening and a t   time of visible disease pr ogression.  
3 For patients assigned to Arm A, research blood will be collecte d for tumor methylation analysis  and other correlative studies on Day 1 of every  
cycle.  
4 For patients assigned to Arm B, research blood will be collecte d for tumor methylation analysis and other correlative studies at screening and/or 
Cycle [ADDRESS_1036308]  cycle beginning with Cycle 4 (Cycle 4, 7, 10).  
[ADDRESS_1036309]/abdom en/pelvis (CT preferred, abdom inal/pelvis MRI will be performed for patients with CT contrast  allergy) and 
any other imaging required per R ECIST for the particular subjec t are required at baseline must be obtained within [ADDRESS_1036310] cycle, beginning w ith Cycle 4 (Cycles 4, 7, 10). Fo r each individual 
patient, the same imaging moda lity should be used at assessment  as was used during screening.  
[ADDRESS_1036311].  
14 Completed only if FACIT data not collected at time of visible d isease progression  
    
SKCCC J12138  
      IND 117362 
    Confidential    
16 
Version 10.0 / July 2, 2020  15 Tumor assessments should ideally be performed within a +/- 2 we ek window every 3 months (Cycle,  4, 7, and 10). Ho wever, Tumor assessment 
may be completed at the patient ’s oncologist’s discretion outsi de of the ideal window 
16 May be obtained any time throughout the study for both Arm A an d Arm B patients.  
17 Assessment not required for Arm B patients 
18 For Arm B patients CA19-9 may be c ollected outside of the recom mended 3 month window at the patie nt’s local oncologist’s discr etion. 
[ADDRESS_1036312] aff. 
20 CC-486 dosing (D1-21) research drug  may be shipped to patients to limit contact [CONTACT_757019]-19 precautions. See Section [IP_ADDRESS]  for more 
details. 
21 Review of remaining pi[INVESTIGATOR_756970]  a telemedicine visit when drug is unable to be returned to stu dy staff due to 
COVID-19 precautions. Copi[INVESTIGATOR_1309] t he pi[INVESTIGATOR_756971], email, fax, or mychart. 
   
  
    
SKCCC J12138  
      IND 117362 
    Confidential    
17 
Version 10.0 / July 2, 2020  2.2 Schedule during Follow Up – All Subjects*  
Assessments are to be completed within 3 months of safety assessment/progression/previous follow-up 
Schedule variations for CA19-9 and Imaging assessments permitted 
Procedure * Follow Up  
 (Until 2nd disease 
progression) Survival  
Follow-Up** 
(<  3mo of previous follow up)
Information on new cancer therap ies (records to be obtained) X  
Subjective response to therapi[INVESTIGATOR_014]  (records to be obtained) X  
CA 19-9 (records to be obtained)  X  
Imaging completed (reco rds to be obtained)  X  
Study team contact*** X X 
 
*   For Arm B patients, follow up will be completed within 3 months  of cycle 10 or within 3 months of disease progression. For Arm  A patients, 
follow up will be completed within 3 months of safety assessmen t. If safety assessment was not completed, follow up will begin  within 3 months 
of progression/discontinuation of drug. Follow Up assessments a re ideally to be completed on a [ADDRESS_1036313]’s 
discretion. An attempt to contac t patients and obtain informati on on new cancer therapi[INVESTIGATOR_13265] s ubjective responses to such the rapi[INVESTIGATOR_756972] 3 months of the  previous follow up.   
** Survival Follow-Up will begin once the patient is deemed to have progressive disease for the second time. If the patient ha s not progressed and 
was put on Follow Up for reasons o ther than visible disease pro gression, patient must still have  two instances of visible dise ase progression until 
being on the Survival Follow Up schedule. Patients will remain on the selected Follow-Up schedule for a combined total of up t o [ADDRESS_1036314] withdraws consen t (whichever occurs first). 
*** Study team will attempt to contact [CONTACT_757020]/ her survival status, and any o ther comments/information 
per PI’s request. While it is preferred the study team contacts  the patient for follow-up, this  information may also be obtain ed through medical 
records and obituaries.  
 
SKCCC J12138 
IND 117362  
Confidential              
  
18 
Version 11.0 / February 18, [ADDRESS_1036315] 20% of patients are surgical candidate s 
and thus potentially curable, however the majority will recur a nd eventually die of their disease.  
Their median survival is still under 2 years with a 20% 5-year survival2-4.  A standard adjuvant 
treatment approach for patients with resected disease has not y et been determined, although 
chemotherapy or chemoradiation therapy is most commonly used.  Patients that have positive 
lymph nodes (negative nodes is N0, positive nodes is N1) or pos itive margins (negative margin is 
R0, microscopic is R1) at the time of their resection have a ve ry high risk of developi[INVESTIGATOR_756973].  In the event of tumor recurrence, 
defined as visible disease present on imaging, further chemothe rapy is given.  However, an earlier 
sign of recurrence is sometimes a rising blood CA 19-9 level, a  tumor marker indicative of 
presence of disease, without visible tumor seen on imaging.  Ou r goal is to give these patients 
who are high risk of recurrence (N1 disease, R1 margins, or ele vated CA 19-9) a therapeutic 
option before their disease reveals itself on imaging.  Epi[INVESTIGATOR_756974].   This project aims to slow the 
recurrence of pancreatic cancer in these high risk patients by [CONTACT_757021][INVESTIGATOR_756975], 
azacitidine.  
 
Positive lymph nodes found at the time of resection have been c onsistently shown to be a poor 
prognostic factor for overall survival in resected pancreatic a denocarcinoma5.  As a result of this, 
lymph node status is incorporated into the AJCC staging classif ication.  Patients with positive 
nodes regardless of being T1, T2 or T3 disease are stage IIB6.  It is recommended that a minimum 
of 12-15 nodes should be removed during a pancreaticoduodenecto my procedure (Whipple) in 
order to accurately stage a patient as node  positive or node ne gative.  This number was shown to 
be critical when [ADDRESS_1036316] Whipple versus extended 
SKCCC J12138 
IND 117362  
Confidential              
  
19 
Version 11.0 / February 18, [ADDRESS_1036317] and the extended group, the patients with node positive 
disease had about an 11-19% decrease in survival at 1 year and 21-44% decrease at 3 years when 
compared to the node negative patients and there was no differe nce in survival among the surgery 
groups9.  In a retrospective review of 1423 patients who underwent Whi pple procedures from 
1970 to 2006 at The Johns Hopkins Hospi[INVESTIGATOR_307], 78% had positive ly mph nodes.  On multivariate 
analysis, positive lymph node status was a predictor for shorte r survival10. Nodal involvement 
was also shown to be an independ ent predictor of worse outcome in an analysis of a phase II 
Japanese trial of neoadjuvant therapy11, an MD Anderson retrospective review12, as well as in the 
RTOG [ADDRESS_1036318] ratio for N0 disease was 0.63 when compared to patients with 
1-3 positive nodes13.  A large meta-analys is again showed that median survival acro ss all studies 
of N0 patients was 25 months as co mpared to 13.6 months for all  of the N1 patients14.  
The relationship between positive margins and worse survival ha s not been as conclusively 
determined.5 Both the Johns Hopkins Hospi[INVESTIGATOR_307]10 and the MD Anderson12 reviews demonstrated 
that positive resection margins were independent predictors of decreased survival.  The large 
meta-analysis also demonstrated an increase in survival from 10 .3 months for all patients with R1 
resections compared to 20.3 months for patients with R0 resecti ons14. The benefit of an R0 
resection was proven to improve overall survival despi[INVESTIGATOR_040] a larg er surgery when a retrospective 
review compared patients who had pancreaticoduodenectomy with a positive pancreatic neck 
margin with patients who were converted to a total pancreatectomy and had negative margins.  
Median overall survival was 10 months in the R1 group versus 18  months in the R0 group15.  
However, margin status wasn’t a significant factor in a multiva riate analysis in a retrospective 
study of [ADDRESS_1036319]-op CA 19-9 ≥ 180 had a median 
survival of 9 months compared to 21 months when CA 19-9 < [ZIP_CODE].  Patients who undergo 
resection and adjuvant therapy are monitored with imaging and C A  [ADDRESS_1036320] undergone surgery at J ohns Hopkins and continue to be 
followed here to further clarify this observation.   

SKCCC J12138 
IND 117362  
Confidential              
  
20 
Version 11.0 / February 18, 2022    
 
 
  
3.2 Epi[INVESTIGATOR_756976].  DNA methylation, a type of epi[INVESTIGATOR_119991], 
occurs when DNA methyltransferases transfer a methyl group onto  the 5’ carbon of the cytosine 
pyrimidine ring of promoter regions of genes.  These promoter r egions are characterized by a high 
number of cytosine-guanine dinuc leotides, called CpG islands.  When the CpG islands are 
unmethylated, this leads to an open chromatin state that allows  for the transcription of the gene 
that follows this promoter region. Conversely, when the CpG isl ands are hypermethylated, the 
chromatin is closed and transcr iption of the gene is suppressed .  Therefore, hypermethylated 
promoter regions silence the gene which follows.  In the normal  cell, DNA methylation occurs in 
varying amounts throughout the gen ome in order to control gene expression.  This process is often 
abnormal in cancer cells19-21.    
Tumor suppressor genes are a larg e category of genes that contr ol cell proliferation through 
various mechanisms like regulating the cell cycle, repairing da maged DNA, and encouraging 
apoptosis22.  They act as the stop signals for cells. However, when these genes are inactivated, 
cell growth is not properly controlled and damaged cells can ac cumulate and lead to tumorgenesis.  
In normal cells, the promoter r egions for these tumor suppresso r genes are unmet hylated thereby 
[CONTACT_757022].  In cancer cells, howe ver, some of these promoter regions 
are hypermethylated leading to ina ctivation and silencing of th e tumor suppressor gene20, 23.  This 
mechanism is a very intriguing target for cancer therapy as DNA  methylation, like other 
epi[INVESTIGATOR_119991], is reversible20, 23.  
3.3 5-Azacitidine  
5-Azacitidine (AZA) and 5-aza-2 ’-deoxycytidine (decitabine, DAC ) are pyrimidine nucleoside 
analogs of cytidine, both with 5’ modifications of the ring.  T hese drugs were initially used at 
high doses in the 1970’s as cytotoxic agents, mainly in hematol ogic malignancies.  They have 
since been shown to promote DNA hypomethylation at lower doses by [CONTACT_757023], irreversibly binding to DNA methyltransferases, and causing decreased 
methylation in daughter cells.  This allows for reactivation of  tumor suppressor genes leading to 
cessation of cancer cell growth, cancer cell damage and ultimat ely cancer cell death24.   I n  
myelodysplastic syndrome and in elderly patients with acute mye logenous leukemia, AZA and 
DAC have demonstrated improved overall survival and time to leu kemia progression25-27.   A  

SKCCC J12138 
IND 117362  
Confidential              
  
21 
Version 11.0 / February 18, [ADDRESS_1036321] 
effective in situations when time is available.    
While this phase III data was done using a subcutaneous adminis tration of azacitidine, the oral 
formulation, CC-486, (typi[INVESTIGATOR_897] g iven for 7-21 days and repeate d every 28 day cycle) is currently 
being studied in early phase tr ials in this patient population.   It was first shown to be safe at a low 
dose in a pi[INVESTIGATOR_756977] 200830.  In the phase I study supported by [CONTACT_757024]-486,  41 patients wi t h  M D S ,  C M M L  o r  A M L  
refractory or inappropriate for c onventional therapi[INVESTIGATOR_756978]-486 given days 1-7 of ever y 28 day cycle.  The maximum 
tolerated dose (MTD) was 480 mg.  The dose limiting toxicity wa s severe diarrhea, experienced 
in 2 of 3 of the patients at the 600 mg dose.  Nausea, vomiting , headache, fatigue, fever, cough 
and febrile neutropenia were the  other grade 3 adverse events o bserved.  8 patients were still 
receiving the study drug at the t ime of the paper’s publication .  CC-486 was rapi[INVESTIGATOR_19627] 
a mean bioavailability at the MTD of 13%.  CC-[ADDRESS_1036322] at day 15 of each cycle, althou gh not to the same extent as 
subcutaneous azacitidine.  Clinical responses were seen in 35% of patients with MDS and CMML 
who were previously treated and in 73% of patients who received  this as first-line therapy.  
Therefore, CC-[ADDRESS_1036323] cycle.  T his poster demonstrated data f rom patients who in 28 day cycles 
took CC-486 200 mg days 1-14, 200 mg days 1-21, 300 mg days 1-1 4, and 300 mg days 1-21.  
The 300 mg given days 1-21 of a 28 day cycle demonstrated reduc ed DNA methylation, provided 
56% of the cumulative exposure to 5azacitidine as compared to [ADDRESS_1036324] ric adenocarcinoma to allow fo r the re-expression of the tumor 
suppressor gene TSLC132 and ID433, respectively.  Epi[INVESTIGATOR_756979] i n 
SKCCC J12138 
IND 117362  
Confidential              
  
22 
Version 11.0 / February 18, [ADDRESS_1036325] of the studies used subcutaneous azacitidine, however some 
recent phase I trials are investigating the use of the oral for mulation, CC-486.   
 
 
 
 
 
 
 
 
 
 
    
 
In pancreatic cancer, hypermethyl ation of the promoter regions of mismatch repair genes 
(hMLHI )34, growth inhibitory genes ( ARHI )35, cell cycle control genes ( Cyclin D2 )36, and 
proapoptotic genes ( TNFRSF10c37, TMS138, and CRABP239) have been shown to lead to the loss 
of expression of those genes which contributes to tumor growth.   When DAC was added to 
pancreatic cancer cells that e xhibited hypermethylation of the gene ARHI , ARHI  was reexpressed, 
cell growth was inhibited by [CONTACT_34120] 50%, and apoptosis was incr eased by 10-fold.  Pancreatic 
cancer cells were then implanted  into mouse xenografts, DAC was  added to half of the cohort, 
and the mice were sacrificed after 3, 5, 7, or 9 days.  As comp ared to the control mice, those that 
w e r e  t r e a t e d  w i t h  D A C  h a d  a  d e c r e ase in the volume of their tum or by 52% after 3 days of 
treatment and by 92% after 9 days, demonstrating that the addit ion of a hypomethylating agent 
can slow the growth of the tumor35.  Pancreatic cancer cell lines with hypermethylation of 
TNFRSF10c  also showed an increase in gene expression by [CONTACT_8622] 8 times, a  decrease in promoter 
region methylation by [CONTACT_46431] 50%, as well as an increase in apopt osis with the addition of DAC37.  
When AZA was added to pancreatic cancer cells with hypermethyla ted TMS1, there was a 2.5 
fold increase in TMS1 expression. Furthermore, when gemcitabine or docetaxel were ad ded to the 
cells, the ones that were pre-treated with AZA had a 25-30% increase in cell death after the chemotherapy as compared to the  cells without pre-treatment
38.  Lack of expression of CRABP2 
in pancreatic cell lines has been shown to make them resistant to treatment with retinoic acid.  The 
promoter regions were found to be hypermethylated in these resi stant cell lines and expression of 
CRABP2 was increased with the treatment of DAC.  As CRABP2 over  expression is known to 
cause apoptosis in other types of  tumor cell lines, increasing its expression may make these cells 
more sensitive to treatment including retinoic acid39.  More recently, a putative tumor suppressor 
gene, myeloid/lymphoid or mixed-lineage leukemia 3 (MLL3) has b een shown to have 
diminished expression in pancreatic tumor cell lines, tumor xenografts and archived patient 

SKCCC J12138 
IND 117362  
Confidential              
  
23 
Version 11.0 / February 18, [ADDRESS_1036326] that contribute to the 
chemotherapy resistance seen in pancreatic cancers.  This data supports our hypothesis that 
pretreating patients with CC-486 will impair tumor growth and i ncrease their sensitivity to 
chemotherapy.  
3.3.1 Indication and Usage  
5-Azacitidine is indicated for treatment of patients with both low and high-risk myelodysplastic 
syndrome (MDS) for the following French-American-British (FAB) subtypes: refractory anemia 
(RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by [CONTACT_757025]), refractory anemia with excess blasts (RAEB), 
refractory anemia with excess blasts in transformation (RAEB-T) , and chronic myelomonocytic 
leukemia (CMMoL).  It is also considered a category 2B recommen dation per the NCCN 
guidelines (based on lower-level  evidence with a non-uniform NC CN consensus but no major 
disagreement) for elderly patients with AML who cannot receive conventional high-intensity 
chemotherapy.  
3.3.[ADDRESS_1036327] common adverse reactions (>30%) for the subcutaneous r oute per the package insert 
are: nausea, anemia, thrombocytopenia, vomiting, pyrexia, leuko penia, diarrhea, injection site 
erythema, constipation, neutropenia and ecchymosis.  The most c ommon adverse reactions by [CONTACT_757026] , rigors, weakness and hypokalemia.    
 
The most common adverse reactions for the oral route (CC-486) per the phase I trial were: 
diarrhea, nausea, constipation, vomiting, abdominal pain, heada che, fatigue, peripheral edema, 
fever, cough, confusion, dizziness and febrile neutropenia.  Th e DLT was diarrhea
31.  
 
 
 
   
 
 
 

SKCCC J12138 
IND 117362  
Confidential              
  
24 
Version 11.0 / February 18, [ADDRESS_1036328] igational Drug Brochure and the 
IND Safety Letters.  
3.4 Rationale for Treatment in this Setting  
Pancreatic cancer is a highly aggressive malignancy.  Increasin g preclinical and clinical evidence 
has suggested that epi[INVESTIGATOR_18193] t herapy requires several months t o achieve optimal efficacy, 
creating a great challenge in a rapi[INVESTIGATOR_756980].  Hi gh-risk pancreatic cancer patients 
with positive nodal disease, pos itive resection margins, and/or elevated CA 19-9, are a unique 
patient population to test this type of treatment.  The window of time until disease progression 
provides an ideal opportunity to employ epi[INVESTIGATOR_278211].  Cu rrently, there is no consensus as 
to how one should treat patients with pancreatic cancer who hav e undergone resection and 
adjuvant therapy but have an elevated CA 19-9.  Although CA 19-9 has a variable specificity for 
identifying pancreatic adenocar cinoma, its continual rise in a patient with previously known 
disease highly suggests microscopic recurrence, despi[INVESTIGATOR_040] a lack of visible disease on scans.  
Physicians hesitate to give conventional cytotoxic chemotherapy  in the absence of clear disease; 
however patients and physicians are left unsettled given the kn owledge that the disease is 
recurring.  Similarly, patients who have N1 disease or R1 resec tions are not typi[INVESTIGATOR_756981] e absence of disease; however 
virtually all of these patients will recur.  Azacitidine is a v ery well tolerated therapy that can be 
given to patients in this time p eriod without significant toxic ity.  Preclinical models demonstrate 
that multiple tumor suppressor genes have abnormally hypermethy lated promoter regions in 
pancreatic cancer, therefore AZA would allow for these genes to  be reactivated and to slow tumor 

SKCCC J12138 
IND 117362  
Confidential              
  
25 
Version 11.0 / February 18, 2022   growth.  Furthermore, there is preclinical and clinical data in  other solid tumors that suggests that 
AZA may prime the cancer to improve its response to chemotherap y – a hypothesis that our study 
will also test.    
3.[ADDRESS_1036329] pati ents who will be responders versus 
non-responders and identify predic tive signatures of possible r ecurrence and benefits of CC-486 
therapy.  
 
Blood for correlative studies will be drawn from both Arm A and  Arm B patients at screening 
and/or on Day [ADDRESS_1036330] three months.  
 
These correlative studies are done in order to evaluate the met hylation status of free tumor DNA 
circulating in the blood.  Quant itative analysis using real-tim e Methylation-specific PCR (MSP) 
will be used to detect the presence of methylated alleles for s pecific genes. Candidate genes found 
to be hypermethylated in pre-treatment samples will be monitore d for changes in methylation 
during and after treatment using real-time MSP.  Methylation st atus analysis will also be done on 
pre-treatment and post-treatment samples using a novel nano-ena bled methylation based 
technology, Methylation-on-Beads.  This assay has shown great p romise as a tool for surveillance 
of responses to epi[INVESTIGATOR_756982].  Blood will also be stored to use in the future if new biomarkers 
are developed that may bette r predict recurrence.  
 
All patients will also undergo a tumor biopsy at the time of th eir recurrence on scans that will be 
examined with their original re sected pancreatic tumor.  All bi opsy specimens will undergo tumor 
methylation analysis with MSP for select candidate genes ( TMS1 , ARH1 , etc).   Where sufficient 
tissue is obtained, samples will also be studied using HumanMet hylation 450K BeadChip 
(Illumina).  This technology examines over 450,000 CpGs and we will analyze the data and 
integrate the methylome data w ith mRNA or miRNA expression arra y studies.  
SKCCC J12138 
IND 117362  
Confidential              
  
26 
Version 11.0 / February 18, 2022   4 Study Objectives and Endpoints  
4.1 Objectives  
Primary objective:  
To improve progression free survival in patients with resected pancreatic adenocarcinoma who 
have node positive disease, margin positive disease, and/or ele vation in CA 19-9 treated with CC-
486 as compared to observation aft er completion of adjuvant the rapy.  
  
Secondary objectives:  
1) To improve response rates to first line chemotherapy (partial a nd complete response) after 
recurrence in patients treated w ith CC-486 after completing adj uvant therapy   
2) To improve overall survival in patients with resected pancreati c adenocarcinoma treated with 
CC-486.  
3) To evaluate resected pancreatic  cancer tissue and biopsies at t ime of recurrence for epi[INVESTIGATOR_756983] s of CC-486.  
4) To evaluate resected pancreatic cancer tissue and blood samples  t o  i d e n t i f y  p r e d i c t i v e  
signatures of possible recurren ce and the benefit of hypomethyl ating therapy.  
5) To evaluate quality of life  on CC-[ADDRESS_1036331] ionnaire  
4.2 Endpoints  
Primary endpoint  
The primary endpoint of the trial is to demonstrate an increase  in the progression free survival, 
PFS, in resected pancreatic cancer  patients treated with CC-486   
  
Secondary endpoints  
1) Response rate (including partial and complete response) to firs t line chemotherapy when given 
after visible disease recurrenc e in patients primed with CC-486  compared to observation  
2)  Overall survival  
3)  Decreased methylation in candidate genes in the research biops ies as compared to the original 
resected specimens in patients treated with CC-486.  
4) Change in quality of life scor es as determined by [CONTACT_720361]-Hep  
 
SKCCC J12138 
IND 117362  
Confidential              
  
27 
Version 11.0 / February 18, [ADDRESS_1036332]  finished adjuvant chemothera py and/or chemoradiation (or 
were deemed unable to receive adjuvant therapy) with no evidenc e of visible dis ease on imaging 
and have high risk features.  High risk features are defined as  an elevated CA 19-9 level > ULN 
drawn on [ADDRESS_1036333] 2 weeks apart; positive nodal dis ease; and/or positive resection 
margins. The study will be cond ucted at Johns Hopkins Universit y, The University of 
Pennsylvania, [LOCATION_005] General Hospi[INVESTIGATOR_307], and Beth Israel D eaconess Medical Center.  
Patients will be randomized to one of two arms to enable us to evaluate for effects of CC-[ADDRESS_1036334]’s discretion. 
Patients on the observation arm who are unable to travel to stu dy site may be followed by [CONTACT_757027]. When pa tients have visible disease 
recurrence on CT scan, Arm A will stop the CC-[ADDRESS_1036335] visible dis ease progression. Once patients ha ve had a 2nd instance of visible disease 
progression, they will be moved to the survival follow-up sched ule. We will power this study in 
order to see a 64% increase of t he progression free survival be tween the two groups. This will 
require approximately 60 patients to be enrolled and randomized .    
5.1.1 5-Azacitidine Description  
5-Azacitidine is a pyrimidine nucleoside analog of cytidine.  5 -Azacitidine is 4-amino-1-β-
Dribofuranosyl-s-triazin-2(1H)- one. The empi[INVESTIGATOR_24598] C 8H12N4O5. The molecular weight 
is 244.   The structural formula is:  
  
Chemical Structure of 5-Azacitidine    
SKCCC J12138 
IND 117362  
Confidential              
  
28 
Version 11.0 / February 18, 2022     
5-Azacitidine is a white to off-white solid. It was found to be  insoluble in acetone, ethanol, and 
methyl ethyl ketone; slightly s oluble in ethanol/water (50/50),  propylene glycol, and polyethylene 
glycol; sparingly soluble in wat er, water saturated octanol, 5%  dextrose in water, N-methyl-2-
pyrrolidone, normal saline and 5% Tween 80 in water; and solubl e in dimethylsulfoxide (DMSO).  
[IP_ADDRESS] Clinical Pharmacology  
5-Azacitidine is a pyrimidine nuc leoside analog of cytidine.  I t is believed to exert its 
antineoplastic effects by [CONTACT_757028].  The concentration of 5 -azacitidine required for 
maximum inhibition of DNA methylation in vitro  does not cause major suppression of DNA 
synthesis.  Hypomethylation may restore normal function to gene s that are critical for 
differentiation and proliferati on.  The cytotoxic effects of 5- azacitidine cause the death of rapi[INVESTIGATOR_108595], including cancer cells that are no longer respo nsive to normal growth control 
mechanisms. Non-proliferating ce lls are relatively insensitive to 5-azacitidine.  
[IP_ADDRESS] Pharmacokinetics  
The pharmacokinetics of 5-azacitidine were studied in 6 MDS pat ients following a single 75 
mg/m2 subcutaneous (SC) dose and a single 75 mg/m2 intravenous (IV) dose. 5-Azacitidine is 
rapi[INVESTIGATOR_756984]; the peak plasma 5-aza citidine concentration of 750 ± 
403 ng/ml occurred in 0.5 hour. The bioavailability of SC 5-aza citidine relative to IV 5azacitidine 
is approximately 89%, based on area under the curve. Mean volum e of distribution following IV 
dosing is 76 ± 26 L. Mean appare nt SC clearance is 167 ± 49 L/h our and mean half-life after SC 
administration is 41 ± 8 minutes.  
 Published studies indicate that urinary excretion is the primar y route of elimination of 5azacitidine 
and its metabolites. Following IV administration of radioactive  5-azacitidine to 5 cancer patients, 

SKCCC J12138 
IND 117362  
Confidential              
  
29 
Version 11.0 / February 18, 2022   the cumulative urinary excreti on was 85% of the radioactive dos e. Fecal excretion accounted for 
<1% of administered radioactivity over 3 days. Mean excretion o f radioactivity in urine following 
SC administration of 14C-5-azaci tidine was 50%. The mean elimin ation half-lives of total 
radioactivity (5-azacitidine and its metabolites) were similar after IV and SC administrations, 
about 4 hours.  
 
The pharmacokinetics of CC-486 as a single agent were evaluated  in the phase I/II trial in MDS, 
CMML and AML patients.  Plasma and urine studies were done on d ays 1 and 7 of cycle 1 (SQ 
dosing) and cycle 2 (oral dosing).  Rapid absorption was seen i n both routes as the maximum 
observed plasma concentration (C max) was reached within 0.5 hours with SQ dosing and 1.0 hours 
with oral dosing.  The mean elim ination half-life was 1.6 ± 0.7  hours for SC and 0.62 ± 0.25 hours 
for oral and the concentration decreased in a pseudobiphasic ma nner.  The MTD had a mean 
relative bioavailability of 13% ±  9%.  Apparent volume of distr ibution was greater than total body 
water and apparent total clearance was greater than hepatic blo od flow, suggestive wide tissue 
distribution and extrahepatic metabolism, respectively.  Less t han 2% of azacitidine was 
recovered in urine in both SQ and oral forms, implying the main  elimination pathway is not renal.  
Tests after multiple doses suggest no azacitidine accumulation31.  
[IP_ADDRESS] Handling, Storage, and Disposal of CC-[ADDRESS_1036336] w ith mucous membranes, flush t horoughly with water.  
 
CC-486 will be supplied as 100 mg tablets.  Each tablet is form ulated using excipi[INVESTIGATOR_756985].  Further details can be found 
in the CC-486 Investigator’s Brochure.  There is no need to pro tect CC-486 from exposure to 
light.  
 
Each tablet will be sealed in a blister package.  CC-486 tablet s should be stored at 25oC (77oF), 
excursions permitted to 15oC to 30oC (59oF to 86oF), and free of environmental extremes.  The 
storage area should be secure and have limited access.  Shelf-l ife evaluations of the intact blister 
packages, pouches, and HDPE bottles are ongoing.  The CC-486 st udy drug will be monitored for 
stability for the dura tion of the study.   
SKCCC J12138 
IND 117362  
Confidential              
  
30 
Version 11.0 / February 18, [ADDRESS_1036337] meet the followi ng inclusion criteria to be eligi ble for the study:  
1. Understand and voluntarily sign an informed consent form.  
2. Age ≥[ADDRESS_1036338] a histologically confirmed pancreatic adenoc arcinoma that has had an 
R0 (negative margins) or R1 (microscopi[INVESTIGATOR_752747]) resection.  
5. Subjects must have finished adj uvant therapy, which can include  chemotherapy and/or 
chemoradiation therapy or have been determined to be unable to take adjuvant therapy.  
Although patients will be expected to complete chemoradiation o r chemotherapy per 
physician recommendations, patients who are unable to complete chemotherapy ± 
radiation therapy secondary to dose limiting toxicities will be  eligible provided they meet 
study criteria.   
6. Subjects enrolled due to node + disease or R1 resection must be  able to undergo 
randomization within [ADDRESS_1036339] a CA 19-9 value > the institutional U LN on two separate checks 
at least [ADDRESS_1036340] be free of visible disease on imaging (CT, PETCT or MRI) evaluating chest, 
abdomen, and pelvis within 28 days of enrollment on the study.  
10. Life expectancy of greater than 12 weeks  
11. ECOG performance status of ≥ 1 a t study entry (see Appendix A).   
12. Subjects must have normal organ a nd marrow function as defined below:  
SKCCC J12138 
IND 117362  
Confidential              
  
31 
Version 11.0 / February 18, 2022   • Absolute neutrophil count ≥ 1500/mm³   
• Leukocytes ≥ 3,000/mm3  
• Platelet count ≥ 100,000/mm³   
• Hemoglobin > 9.0 g/dL  
• Serum creatinine levels < 2 mg/dL  
• Serum bilirubin levels ≤1.5 mg/dL   
• AST (SGOT) and ALT (SGPT) ≤ 2.[ADDRESS_1036341]  
• Alkaline phosphatase ≤ 2.[ADDRESS_1036342]  
13. Free of prior malignancies for ≥ [ADDRESS_1036343] < Grade 2 pre- existing peripheral neuropathy  (per CTCAE)  
5.2.2 Exclusion criteria   
Subjects who meet any of the fo llowing exclusion criteria are n ot eligible for the study:  
1. Any serious medical condition, laboratory abnormality, or psych iatric illness that would 
prevent the subject from signi ng the informed consent form.  
2. Pregnant or breastfeeding women.  
3. Use of any other chemotherapy, radiotherapy, or experimental dr ug or therapy within 4 
weeks (6 weeks for nitrosoureas or mitomycin C) prior to enroll ment on study or those 
who have not recovered from adverse events ≥ grade 1 due to age nts administered more 
than 4 weeks earlier except fo r stable grade 2 neuropathy.  
4. Subjects may not receive any other concomitant investigational agents.  
5. Known or suspected hypersensiti vity to 5-azacitidine or mannito l  
SKCCC J12138 
IND 117362  
Confidential              
  
32 
Version 11.0 / February 18, [ADDRESS_1036344] ess including, but not limited to , ongoing or active infection, 
symptomatic congestive heart failure, unstable angina pectoris,  cardiac arrhythmia, or 
psychiatric illness/social situ ations that would limit complian ce with study requirements.  
8. Any known gastrointestinal disor ders which would preclude oral administration of 
5azacitidine.  
5.2.3 Inclusion of Women and Minorities  
Both men and women and members of all races and ethnic groups a re eligible for this trial.  
5.2.4 Patient Recruitment   
Patients will be contact[CONTACT_757029].  In addition, t he schedule of Whipple surgeries 
will be requested on a weekly basis from the operating room sch edulers.  Patients eligible for the 
study will then be contact[CONTACT_647474] e by [CONTACT_093].   
5.2.5 Protocol and Drug Administration  
This study will be conducted in accordance with the Sidney Kimm el Comprehensive Cancer 
Center’s Coordinating Center Protocol.  
5.2.6 Multicenter Guidelines  
 Protocol Chair  
  The Protocol Chair is responsib le for performing the followin g tasks:  
• Coordinating, developi[INVESTIGATOR_007], submitting, and obtaining approval fo r the protocol as well 
as its subsequent amendments.  
• Assuring that all participating in stitutions are using the corr ect version of the protocol.  
• Taking responsibility for the overall conduct of the study at a ll participating 
institutions and for monitoring t he progress of the study.  
• Reviewing and ensuring reporting of Serious Adverse Events (SAE )   Reviewing 
data from all sites.  
  
Coordinating Center  
  The Coordinating Center is res ponsible for performing the fol lowing tasks:  
• Ensuring that IRB approval has b een obtained at each participat ing site prior to the 
first patient registration at that site, and maintaining copi[INVESTIGATOR_302259].  
SKCCC J12138 
IND 117362  
Confidential              
  
33 
Version 11.0 / February 18, 2022   • Managing central patient registration.  
• Collecting and compi[INVESTIGATOR_54924].  
• Establishing procedures for documentation, reporting, and submitting of AE’s and 
SAE’s to the Protocol Chair, and all appli cable parties.  
• Facilitating audits by [CONTACT_302309] r esearch records from 
participating sites for audit , or by [CONTACT_54966].  
  
Participating Sites  
  Participating sites are responsible for performing the follow ing tasks:  
• Following the protocol as writte n, and the guidelines of Good Clinical Practice (GCP).  
• Submitting data to the Coordinating Center.  
• Registering all patients with the  Coordinating Center by [CONTACT_757030], and signed informed consent promptly.  
• Providing sufficient experienced clinical and administrative st aff and adequate 
facilities and equipment to conduct a collaborative trial accor ding to the protocol.  
• Maintaining regulatory binders o n site and providing copi[INVESTIGATOR_594590].  
• Collecting and submitting data according to the schedule specif ied by [CONTACT_760].  
  
5.2.[ADDRESS_1036345] send the following documents to Sheila Linden at the Coordinating 
Center by [CONTACT_25541]  
• Registr ation Form  
• HIPAA authorization form (i f separate from consent)  
• Eligibility screen ing checklist  
• Copy of all required screening tests.  
  
The Coordinating Center will review the documents to confirm el igibility.  To complete the 
registration process, the C oordinating Center will:  
• assign a patient study number  
• register the patient on the study w ith the Sidney Kimmel Compre hensive  
Cancer Center’s Clinical Research Office  
• E-mail the patient study number  to the participating site.  

SKCCC J12138 
IND 117362  
Confidential              
  
34 
Version 11.0 / February 18, 2022   5.2.8 Randomization  
Subjects who are eligible to enroll in the study will be random ized in a 1:1 ratio to receive CC486 
or observation.  Subjects will be randomized through a computer  program maintained by [CONTACT_123894].  
• CC-486 (three 100 mg tablets on Days 1-21 every 28 days)  
• Observation  
The randomization will be balan ced by [CONTACT_757031] b locks and will be stratified by 
[CONTACT_4868]:   
• Positive lymph nodes at time of resection (N0 versus N1)   
Approximately 55-75% of patient s are expected to be node positi ve.10, 13, 40-42  
CC-486 will be packaged and desi gnated for a patient upon rando mization to Arm A.  Subsequent 
bottles of study drug will be ma de available to patients as nee ded.  Patient will receive one bottle 
of study drug with no more than 63 tablets in the bottle.  
External sites will submit a patient enrollment log to the Coor dinating Center monthly by [CONTACT_6968], 
at   
5.2.9 Dosage Dispensing and Administration  
Treatm
ent will be administered on an outpatient basis. Reported  adverse events and potential risks 
are described in Section 6.  Appr opriate dose modifications are  described in Section  
 
No investigational or commercial agents or therapi[INVESTIGATOR_756986] t o treat the patient’s malignancy.  
[IP_ADDRESS] Dispensing and Administration of CC-486  
On Day 1 of each cycle, subjects in Arm A will be administered three tablets of 100 mg of CC486 
in clinic with approximately 8 ounces (240mL) of room temperatu re water.  CC-486 may be taken 
on an empty stomach or with food.  Dosing can occur at any time  during the morning after 
completing the required pre-dose assessments.  Time of dose sho uld be recorded in study 
documents.  Anti-emetics can be ad ministered per discretion of the investigator (per Section 5.4.1) 
on an as needed basis.   
 
For each cycle, subjects in Arm A will take the three [ADDRESS_1036346].  Subjects should be instr ucted to return any doses not taken or 

SKCCC J12138 
IND 117362  
Confidential              
  
35 
Version 11.0 / February 18, 2022   any tablet(s) found to be not totally intact to the study clini c on the first day of each cycle, 
beginning with Cycle 2.  Subjects should be instructed to open the study medication packaging as 
close as possible to when they  are going to take the study drug  and record the time of study drug 
administration on a diary card (Appendix B).  The diary card wi ll be returned to clinic staff at the 
end of each cycle.  On days when study drug is taken at home, s ubjects should be encouraged to 
ingest CC-486 with approximately 8 ounces (240mL) of room tempe rature water.  CC-486 may 
be taken on an empty stomach or with food.  
 
If a dose of CC-486 is missed, it should be taken as soon as po ssible on the same day.  If it is 
missed for the entire  day, it should not be made up.  If the pa tient vomits after a dose is taken, no 
more subsequent tablets should be administered.  
The cycle length is 4 weeks (28 days).  Treatment with protocol  therapy will continue until 
unacceptable toxicities or subject  has visible disease progress ion on imaging.  Furth er details per 
Sections [ADDRESS_1036347] 
call the patient to ensure that shipment was received in good c ondition at the patient’s home, and 
instruct patient to keep and retu rn all empty, partially empty,  or full bottles/blisters to the site at 
next visit for drug reconcilia tion. This call, including verbal  confirmation of receipt by [CONTACT_102], 
should be properly documented i n the medical record. If COVID-1 9 precautions prevent the return 
of used/unused study drug supplies to the site, then study staf f must review the remaining pi[INVESTIGATOR_756987] a telemedicine visit. U ndelivered supplies should be ret urned to the c linical site. 
5.2.[ADDRESS_1036348] ug administration (including 
prescribing and dosing).  Subject diaries will be collected at the end of each cycle and at the 
discontinuation of treatment.  
Review of remaining pi[INVESTIGATOR_756988]  a telemedicine visit when drug 
is unable to be returned to st udy staff due to COVID-19 precaut ions. Copi[INVESTIGATOR_756989], fax, email, or mychart. 
5.3 Visit Schedule, Assessments , and Dose Modifications  
Screening assessments and all on-study scheduled visits and ass essments are outlined in Section 
2 Table of Study Assessment s and detailed below.  
 
SKCCC J12138 
IND 117362  
Confidential              
  
36 
Version 11.0 / February 18, [ADDRESS_1036349] of concomitant medications and  procedures, medical history, a 
physical examination, vital signs, weight, ECOG performance sta tus (per Appendix A), 
pregnancy test, labs (CBC with differential, serum chemistry an d hepatic panel, CA 19-9, PT, 
PTT), research labs, quality o f life measures and lesion assess ment with CT (per Section 7).  All 
pre-study assessments should be do ne ≤ 28 days from Cycle 1 Day  1.  
5.3.2 Initial Phase: Assessments, D ose Modifications, and Termi nation  
[IP_ADDRESS] Arm A for first cycle  
Prior to receiving Cycle [ADDRESS_1036350] under go a physical examination 
including vital signs, weight, and ECOG performance status asse ssments, and labs including CBC 
with differential, serum chemistry and hepatic panel, CA 19-9, PT/PTT, and research blood, a 
record of concomitant medications and procedures, quality of li fe, and an assessment of adverse 
events.  If screening assessments were done within 7 days of in itiating Cycle 1 Day 1, these do 
not need to be repeated.  Cycle 1 of CC-486 in Arm A can then b e administered on schedule if 
treatment criteria are met. 
  
[IP_ADDRESS] Arm A for first 12 cycles  
Arm A patients will be evaluated on Day 1 of every cycle with a  physical examination, ECOG 
performance status, vital signs , weight, CBC with differential,  research blood and serum 
chemistry and hepatic panel. Arm A patients will also complete an assessment of adverse events 
and reporting of current medica tions/procedures on Day [ADDRESS_1036351] cycle beginning at Cycle 4.   
 
Arm A subjects will be evaluated  for adverse events on Day 1 of  each cycle with the NCI CTCAE 
v4.0 ( http://ctep.info.nih.gov ) used as a guide for the grading of severity.  For Arm A patie nts, 
doses will be reduced for hematologic and other non-hematologic  toxicities that can be attributed 
to the study drug.  Dose adjustments are to be made according t o the system showi ng the greatest 
degree of toxicity.  When a dose reduction is required for Day 1 of any cycle, no dose re-escalation 
will be permitted for the duration of study treatment.  
 
NOTE: Arm B patients will not be evaluated for adverse events a s they do not receive the study 
agent.  
   Criteria to Initiate Treatment 
SKCCC J12138 
IND 117362  
Confidential              
  
37 
Version 11.0 / February 18, 2022   In Arm A, a new course of treatme nt may begin on the scheduled Day 1 of a new cycle if: 
• Absolute neutrophil count ≥ 1500/mm³ 
• Platelet count ≥ 100,000/mm³ 
• Serum creatinine levels < 2 mg/dL 
• Serum bilirubin levels ≤ 1.5 mg/dL. 
• AST (SGOT) and ALT (SGPT) ≤ 2.5 x the institutional upper lim it (ULN) of the normal 
range 
• Any other drug-related adverse events that may have occurred must have resolved to  
˂ Grade 2 severity except grade  2 anorexia and a ny correctable metabolic abnormality. 
• No evidence of visible diseas e recurrence on imaging (if indi cated per Study Schedule, 
Section 2, to be done prio r to cycles 4, 7, and 10) 
 
If these conditions are not met on Day [ADDRESS_1036352] will be evaluated weekly and 
a new cycle of treatment will no t be initiated until the toxici ty has resolved as described above 
utilizing the dose modifications  as depi[INVESTIGATOR_48393]. If the stud y drug has to be held for > 
28 days, study treatment will be discontinued. 
 
[IP_ADDRESS] Arm B for the first 12 cycles  
Arm B patients will ideally be evaluated (or at the very least contact[CONTACT_38435]) on Day 
[ADDRESS_1036353], and CA19- 9 and lesion assessments may be 
completed outside of the recommended 3 month window (Cycles 4, 7, and 10) at their 
oncologist’s discretion. .  
Arm B patients will follow a similar schedule as patients in Fo llow-up, except for a Quality of 
Life assessment that will be performed.  
Correlative blood draw is optional for Arm B patients. If Arm B  patients wish, they may have 
research bloods drawn for  correlative studies.  
 
Arm B patients who opt to have research blood collected will ha ve it collected on Day [ADDRESS_1036354] cycle (cycle 4, 7 and 10). 
 
Below is the list of informati on that must be obtained from Arm  B patients. 
• Any further therapy receive d (records to be obtained)  
• Subjective response on therapy ( records to be obtained)  
• Any CA 19-9 drawn (records to be obtained)  
• Any imaging (images to be obtained)  
SKCCC J12138 
IND 117362  
Confidential              
  
38 
Version 11.0 / February 18, [ADDRESS_1036355] scan (or alternate 
imaging, if clinically indi cated) quarterl y (ideally).  
Arm B patients who are not evalu ated in person may have the Qua lity of Life assessment 
completed over the phone.  
[IP_ADDRESS] Dose Modification  
Table 5.3.1:  Arm A: Dose Modification Reco mmendations for CC-486 Phase   
Toxicity  Grade  CC-486  
Febrile Neutropenia Grade 3 or 4 Hold until resolved and neutrophils ≥ 1500/mm3  
Restart study drug at 200 mg (two tablets, 33% dose 
reduction).  
If the same Grade 3 or 4 ev ent recurs (i.e., third 
occurrence) despi[INVESTIGATOR_756990]-486 dose reduction to 200 mg, 
as described above, permanently discontinue study 
d
Leukopenia and/or Neutropenia Grade 2-3 Hold dose until recovery to Grade ≤ 1 or baseline. 
Resume study drug at prior dose  
 Grade 4 Hold until resolved to ≤ Grade 1 
Restart study drug at 200 mg (two tablets,  33% dose 
reduction). 
If the same Grade 4 event recu rs (i.e., third occurrence) 
despi[INVESTIGATOR_756990]-486 dose reduction to 200 mg, as described 
above, permanently discontinue study drug. 
Thrombocytopenia Grade 1* or 2 Hold treatment until resolution to normal values. 
Grade 3 or 4 Hold until resolved and platelet count ≥100,000/mm³ 
Restart study drug at 200 mg (two tablets, 33% dose 
reduction).. 
Diarrhea  (unresponsive to 
maximum  medical 
management) Grade 1 or 2 Consider administe ring symptomatic remedies and/or  start 
prophylaxis.  
No dose/schedule changes 
SKCCC J12138 
IND 117362  
Confidential              
  
39 
Version 11.0 / February 18, 2022   Toxicity  Grade  CC-486  
Grade 3 or 4 Hold until resolved to ≤ Grade 1 
Restart study drug at 200 mg (two tablets,  33% dose 
reduction). 
Nausea/Vomiting 
(unresponsive to  maximum 
medical management) Grade 1 or 2 Consider changing/adding antiemetic medication 
treatment   No dose/schedule changes 
Grade 3 or 4 Hold until resolved and neutrophils ≥ 1000/mm3  
Restart study drug at 200 mg (two tablets, 33% dose 
reduction). 
 *Grade 1 thrombocytopenia: P latelet count < 100,000/mm³ 
 
Study drug should be stopped if grade 3 or 4 toxicity has occur red despi[INVESTIGATOR_040] a dose reduction to 66% 
of original dose (200 mg of CC-486 in two 100 mg tablets).  
If grade 3 or 4 toxicities requi re patients to stop treatment m id cycle, they can resume their cycle 
at the recommended decreased dose if the toxicities resolve to ≤ Grade 1 within their 21 days of 
treatment (i.e. they would only continue treatment to complete their days 1-21 per the calendar, 
not to complete 21 days of taking the tablets).  If their toxic ities recover after their 21 days has 
completed, they will not take more tablets until they begin the ir next cycle. 
[IP_ADDRESS] Arm A: Missing doses 
 
Missed Doses Day [ADDRESS_1036356] consider ed omitted.  
5.4 Discontinuation of Treatment: Arm A  
In the absence of treatment delays due to adverse events, treat ment with CC-486 may continue 
until one of the followi ng criteria applies:  
• Interruption of scheduled thera py for greater than four weeks,  
SKCCC J12138 
IND 117362  
Confidential              
  
40 
Version 11.0 / February 18, 2022   • Intercurrent illness that prevents further administration of tr eatment,  
• Adverse event(s) that, in the judgment of the Investigator, may  cause severe or permanent 
harm or which rule out continua tion of the treatment regimen 
• For any grade 3 and 4 toxicity tha t recurs despi[INVESTIGATOR_756991] 
• Discontinuation of CC-486 for any reason,  
• Treatment with other chemotherape utic or investigational anti-n eoplastic drugs,  
• Subject decides to with draw from the study,  
• Suspected pregnancy or positive pregnancy, or  
• General or specific changes in  the subject's condition render t he subject unacceptable for 
further treatment in the judg ment of the investigator, or  
• Disease recurrence on imaging, or  
• Patient has completed one  year of therapy with CC-486.  
If the subject has visible disease recurrence on imaging or mee ts any of the aforementioned criteria 
for removal from study treatment, then the CC-486 or observatio n phase of this study will 
conclude and patient will enter the follow-up phase of the stud y, following the schedule of 
assessments as described in Section [IP_ADDRESS].    
Mandatory research bloods and tu mor biopsies will be obtained a t the time of recurrence for both  
Arm A and Arm B subjects, per the method determined best per th e investigator as outlined on 
the Study Calendar and in Section. 
 
5.4.1 End of Treatment 
When coming off of CC-486 therapy, subjects in Arm A will under go a physical examination, 
vital signs, weight, ECOG performance status, assessment of adv erse events, labs including CBC 
with differential, serum chemistry and hepatic panel, CA 19-9, PT/PTT and resear ch blood. If any 
of these were performed within 7 days, they do not need to be r epeated. All remaining pi[INVESTIGATOR_756992]. 
 
  5.5 Follow-up Phase Both Arms 
No disease recurrence: 
Less than 10% of patients who have undergone surgery will not d evelop tumor recurrence after 
adjuvant therapy.  
Therefore, if patients have not  recurred after one year of ther apy with CC- 486 (Arm A) the drug 
will be discontinued.  
SKCCC J12138 
IND 117362  
Confidential              
  
41 
Version 11.0 / February 18, 2022   Patients in Arm A will undergo a safety assessment 28 days (± 2  days) post the last dose of 
protocol therapy for res olution of toxicity.  
Because Arm B patients do not rec eive study drug, a safety asse ssment will not be performed. 
 
All patients (Arm A and B) will be then be contact[INVESTIGATOR_530] (ideally) every 3 months on to obtain the 
following information about recurrence, survival and anti-cance r treatment (2.2 Study 
Calendar ):  
• Any further therapy receiv ed (records to be obtained)  
• Subjective response on thera py (records to be obtained)  
• Any CA 19-9 drawn (records to be obtained)   
• Any imaging (images to be obtained)  
 
Disease recurrence 
At the time of recurrence, Arm A and Arm B subjects will underg o biopsy of the recurrent lesion 
per the method determined best per the investigator. 
Post recurrence images will be als o obtained (pre -recurrence im ages are optional) 
Thereafter, attempts to contact p atients every 3 months in orde r to obtain lesion assessments/post 
recurrence images, CA19-[ADDRESS_1036357] 30 minutes 
prior to administration of CC-486.  Additional doses may be adm inistered if required.  
Other antiemetic medications (prochlorperazine, lorazepam, etc. ) may also be taken for 
delayed nausea as needed.  Specific anti-emetic regimens are up  to the discretion of the 
investigator.  
2. Diarrhea: If diarrhea occurs dur ing dosing, an antidiarrheal ag ent(s) may be used.  It is 
recommended that patients experiencing diarrhea associated with  CC-486 be managed 
according to the guidelines provided in Appendix C, which are b ased on a publication in 
SKCCC J12138 
IND 117362  
Confidential              
  
42 
Version 11.0 / February 18, 2022   the Journal of Clinical Oncology43.  A dose reduction of CC-486 may be appropriate based 
on the severity of diarrhea observe d and the response to treatm ent intervention.  
3. Contraceptive Therapy: Sexually active men and women of child-b earing potential must 
agree to use effectiv e contraception.  
5.6.[ADDRESS_1036358] CC-486 administration (see Append ix B). Subjects will be asked to 
bring any unused drug and empty drug containers to the research  c e n t e r  a t  t h e i r  n e x t  v i s i t .   
Research personnel will count and record the number of used and  unused drug at each visit and 
reconcile with the medication diary.  
  
6 Adverse events  
6.1 Definitions Adverse Ev ent (AE) Definition  
An adverse event is the development of an undesirable medical c ondition or the deterioration of 
a pre-existing medical condition following or during exposure t o a pharmaceutical product, 
whether or not considered causa lly related to the product.  An undesirable medical condition can 
be symptoms (e.g., nausea, chest  pain), signs (e.g., tachycardi a, enlarged liver) or the abnormal 
results of an investigation (e .g., laboratory findings, electro cardiogram).  In clinical trials, from 
the time of signing an informed consent, an AE can include an u ndesirable medical condition 
occurring at any time, including run-in or washout periods, eve n if no trial treatment has been 
administered. For this trial, Adverse Events and Serious Advers e Events will be collected for Arm 
A patients only, as they are receiving study drug.  
6.1.1 Serious Adverse Event (SAE) Definition   
A serious adverse event is one  that at any dose (including over dose):  
• Results in death  
• Is life-threatening1  
• Requires inpatient hospi[INVESTIGATOR_676154]  
• Results in persistent or signi ficant disability or incapacity2  
• Is a congenital anom aly or birth defect  
SKCCC J12138 
IND 117362  
Confidential              
  
43 
Version 11.0 / February 18, 2022   • Is an important medical event3  
• Pregnancy  
  
1. “Life-threatening” means that the  subject was at immediate risk  of death at the time of 
the serious adverse event; it do es not refer to a serious adver se event that hypothetically 
might have caused death if it were more severe.  
2. “Persistent or significant disa bility or incapacity” means that  there is a substantial 
disruption of a person’s abilit y to carry out normal life funct ions.  
3. Medical and scientif ic judgment should be exercised in deciding  whether expedited 
reporting is appropriate in situat ions where none of the outcom es listed above occurred.  
Important medical events that may not be immediately life-threa tening or result in death 
or hospi[INVESTIGATOR_756993] e intervention to prevent 
one of the other outc omes listed in the def inition above should  also usually be considered 
serious.  Examples of such events  include allergic bronchospasm  requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospi[INVESTIGATOR_059], or the development of drug  dependency or drug abuse.  
A new diagnosis of cancer during the course of a treatment shou ld be considered as 
medically important.   
 
6.[ADDRESS_1036359] be signed and dated by [CONTACT_16529]’s Pri ncipal Investigator.  Participating 
sites must use the SKCCC template for reporting adverse events per SKCCC policy.  Information 
to be provided must include:  
• Subject ID number, and initials  
• Date of the event  
• Description of the event  
• Description of site's r esponse to the event  
• Assessment of the subject's condition  
• Subject's status on the st udy (on study, off study, etc.)  
• Attribution of e vent to study drug  
SKCCC J12138 
IND 117362  
Confidential              
  
44 
Version 11.0 / February 18, 2022    
Participating Sites  
Participating sites are responsible for reporting adverse events to their IRB according to its 
specific requirements and to the C oordinating Center as follows :  
  
Fatal Events  whether anticipated or unanticip ated, and whether or not relat ed to the study must 
be reported to the Coordinating Center within 24 hours  of the participating site Principal 
Investigator's lear ning of the event.  
  
Serious and Unanticipated Adverse Events  as defined above must be reported to the 
Coordinating Center within 24 hours  of the participating site Princ ipal Investigator's learning of  
the event.   
  
Other Serious Adverse Events  which may result in a change to  the protocol, informed consent , 
or risk to subjects as specified in the protocol must be reported within three (3) working days  of 
the participating site Principa l Investigator's learning of the  event.   
  
Adverse Events which result in no change to proto col, informed consent, or risk to subjects must 
be reported to the Coordinati ng Center on a monthly basis.   
  
Adverse event reports are to be emailed to the Coordinating Cen ter at 
. Follow-up reports are to be emailed  to the Coordinating Center as 
necessary.  
  
The 
investigator must also report follow-up information about S AEs within the same time frames.  
  If a non-serious AE becomes serious, this and other relevant fo llow-up information must also be 
provided within the same time frames described above.    
All SAEs for Arm A patients must be collected whether or not th ey are considered causally related 
to the investigational product.  Investigators and other site p ersonnel are responsible for reporting 
all casually related SAEs to their IRB and the Protocol Chair.  
 All SAE’s should be reported to t he Coordinating Center by [CONTACT_133335] l at 
. 
 
Toxicity will be scored using CTCAE Version 4.0 for toxicity an d adverse event reporting.  A 
copy of the CTCAE Version 4.0 can be downloaded from the CTEP h omepage  

SKCCC J12138 
IND 117362  
Confidential              
  
45 
Version 11.0 / February 18, 2022   (http://ctep.info.nih.gov ).  All appropriate treatment areas should have access to a cop y of the 
CTCAE Version 4.0.  All adverse clinical experiences, whether o bserved by [CONTACT_456391], must be  recorded, with details about t he duration and in tensity of each 
epi[INVESTIGATOR_1865], the action taken with respect to the test drug, and th e subject’s outcome.  The investigator 
must evaluate each adverse experi ence for its relationship to t he test drug and for its seriousness.  
The investigator must appraise a ll abnormal laboratory results for their clinical significance.  If 
any abnormal laboratory result is  considered clinically signifi cant, the investigator must provide 
details about the acti on taken with respect  to the test drug an d about the subject ’s outcome. Only 
clinically significant lab abnormalities will be recorded as ad verse events. 
  
6.2.[ADDRESS_1036360]’s last dose o f CC-486, are considered expedited 
reportable events.  If the subject is on CC-486, it is to be di scontinued immediat ely. The pregnancy 
must be reported to Celgene Drug Safety within 24 hours of the Investigator’s knowledge of the 
pregnancy by [CONTACT_202158].  The femal e subject may be referred to 
an obstetrician-gynecologist ( not necessarily one with reproduc tive toxicity experience) or 
another appropriate healthcare pr ofessional for further evaluat ion.  
 
The Investigator will follow the pregnant female until completi on of the pregnancy, and must 
notify Celgene Drug Safety of the outcome of the pregnancy (eit her normal or abnormal outcome) 
as specified below.  The Investigator will provide this informa tion as a follow-up to the initial 
SAE.  
 
If the outcome of the pregnancy meets the criteria for immediat e classification as a SAE (i.e., 
spontaneous abortion [any congenita l anomaly detected in an abo rted fetus is to be documented], 
stillbirth, neonatal death, or c ongenital anomaly), the Investi gator should follow the procedures 
for Expedited Reporting of SAEs to Celgene (i.e., report the ev ent to Celgene Drug Safety by 
[CONTACT_31950] 24 hours of the I nvestigator’s knowledge of th e event).  
 
All neonatal deaths that occur w ithin [ADDRESS_1036361] to 
causality, as SAEs.  In addition, any infant death after 30 day s that the Investigator suspects is 
related to the in utero  exposure to CC-486 should also be reported.  In the case of a live “normal” 
birth, Celgene Drug Safety should b e advised as soon as the inf ormation is available.  
  
If a female partner of a male subject taking CC-[ADDRESS_1036362] should notify the Inve stigator, and the pregnant pa rtner should be advices to call their 
healthcare provider immediately.  
SKCCC J12138 
IND 117362  
Confidential              
  
46 
Version 11.0 / February 18, [ADDRESS_1036363] Information:  
Celgene Corporation  
 
  
  
  
     
      
 
6.[ADDRESS_1036364] of the study will comply with all FDA safety report ing requirements.    
6.3.1 Expedited reporting by i nvestigator to Celgene  
Serious adverse events (SAE) are  defined above.  The investigat or must inform Celgene in writing 
using a Celgene SAE form or MEDWATCH 3500A form of any SAE with in [ADDRESS_1036365] be completed and s upplied to Celgene by [CONTACT_170071] 24 hours/[ADDRESS_1036366](s), if 
available.  Information not avail able at the time of the initia l report (e.g., an end date for the 
adverse event or laboratory values received after the report) must be documented on a follow-up 
report.  A final report to document resolution of the SAE is re quired.  The Celgene tracking 
number ( OA-PANC-PI-0294 ) and the institutional protocol number should be included on S AE 
reports (or on the fax cover le tter) sent to Celgene.  A copy o f the fax transmission confirmation 
of the SAE report to Celgene should be attached to the SAE and retained with the subject records.  
6.3.2 Report of Adverse Events to the Institutional Review Boar d  
The principal Investigator [INVESTIGATOR_756994]/her Institutional Review Board (IRB) of a 
serious adverse event according to institutional policy. 
    
6.3.3 Investigator Reporting to the FDA  
Serious adverse events (SAEs) that are  unlisted/unexpected, and at least possibly associated 
to 5-azacitadine,  and that have not previously been reported in the Investigator ’s brochure, or 
reference safety information document should be reported prompt ly to the Food and Drug 
Administration (FDA) by [CONTACT_757032].   Fatal or life threatening SAEs 
that meet the criteria for reporting to the FDA must be reporte d to the FDA within [ADDRESS_1036367] 
be reported to the FDA within 15 calendar days after awareness of the event by [CONTACT_106507].  

SKCCC J12138 
IND 117362  
Confidential              
  
47 
Version 11.0 / February 18, [ADDRESS_1036368] ug or disease related.     
 
In accordance with the regulat ion 21 CFR § 312. 33, the IND Spon sor shall within [ADDRESS_1036369] submit a brief r eport of the adverse events and 
progress of the investigation.  Please refer to Code of Federal  Regulations, 21 CFR § 312.[ADDRESS_1036370] of the elements required  for the annual report.  All IND  annual reports will be submitted to 
the FDA by [CONTACT_9533].  
6.4 Adverse event updates/IND safety reports  
Celgene shall notify the Investig ator via an IND Safety Report of the following information:  
• Any AE associated with the use of drug in this study or in othe r studies that is both serious 
and unexpected.  
• Any finding from tests in laborat ory animals that suggests a si gnificant risk for human 
subjects including reports of m utagenicity, teratogenicity, or carcinogenicity.  
The Investigator shall notify hi s/her IRB/EC promptly of these new serious and unexpected AE(s) 
or significant risks to subjects.  
 
The Investigator must keep copi[INVESTIGATOR_56594], includ ing correspondence with Celgene 
and the IRB/EC, on file (see Sect ion 12.4 for records retention  information).  
[ADDRESS_1036371] occur within ≤28 days of initi ation of the CC-486 /observation 
phase to document lack of visible disease on imaging as indicat ed in Section 2, Schedule of Study 
Assessments.  Acceptable imaging modalities are described below  and must include imaging of 
the chest, abdomen and pelvis.  To be declared free of visible disease, there can be no evidence 
of measurable disease, as defi ned below, or presence of maligna nt effusions.   
 
All effusions that can safely be diagnostically d rained must be  evaluated prior to enrolling to 
document lack of malignant cells via thoracentesis or paracente sis.  Fluid that is non-specific or 
too small to drain is considered no visible disease.  If there is a concern for bone metastasis or 
brain metastasis based on clinical symptoms, bone scan and/or b rain MRI must be done to rule 
out metastatic disease prior to  enrolling on this study.  These  scans do not need to be done in the 
absence of concerning clinical symptoms.  
SKCCC J12138 
IND 117362  
Confidential              
  
48 
Version 11.0 / February 18, 2022   Imaging will be performed every 3 cycles while on the CC-486. I deally, imaging will be 
performed every 3 cycles for patients on the observation arm, b ut ultimately imaging/lesion 
assessments will be performed at the patient or his/her oncolog ist’s discretion. When patients have 
evidence of measurable disease, as defined below, they will the n be classified as having “visible 
disease”.  If a lesion or effusion appears but is not confirmed  to be disease until a later time point, 
the time noted for a patient to have “visible disease” should r evert back to the time the lesion or 
effusion initially appeared.  They will stop the CC-486 /observ ation phase and enter the follow 
up phase.  Imaging assessment ideally should occur within < [ADDRESS_1036372]-line 
chemotherapy. If there is a delay between initial documentation  of visible disease and starting 
treatment, imaging may be repeat ed as indicated in Section 2, S chedule of Study Assessments to 
get a true baseline.  
7.2 Definitions of Measurable and Non-Measurable Disease  
• Measurable disease is defined as  at least one lesion whose long est diameter can be 
accurately measured as > 1.[ADDRESS_1036373] component of a  PET/CT, or MRI. 
Clinical lesions will only be considered measurable if they mee t the conditions of Section 
7.3.   
• Note:  Tumor lesions that are s ituated in a previously irradiat ed area might or might not 
be considered measurable.  
• Malignant lymph nodes. To be consi dered pathologically enlarged  and measurable, a 
lymph node must be > 1.[ADDRESS_1036374] s can (CT scan slice 
thickness recommended to be no greater than 5 mm). At baseline and in follow-up, only 
the short axis will be measured and followed.  
• All other lesions (or sites of di sease), including small lesion s (longest diameter < 1 cm or 
pathological lymph nodes with ≥ 1 to <1.5 cm short axis) are co nsidered nonmeasurable 
disease.  Bone lesions, leptomeningeal disease, ascites, pleura l/pericardial effusions, 
lymphangitis cutis/pulmonis, inflammatory breast disease, and a bdominal masses (not 
followed by [CONTACT_462]), are considered non-measurable.  
• Note: Cystic lesions that meet t he criteria for radiographicall y defined simple cysts should 
not be considered as malignant lesions (neither measurable nor non-measurable) since 
they are, by [CONTACT_108], simple c ysts. ‘Cystic lesions’ thought  to represent cystic metastases 
can be considered as measurable lesions, if they meet the defin ition of measurability 
described above. However, if non- cystic lesions are present in the same subject, these are 
preferred for selecti on as target lesions.  
SKCCC J12138 
IND 117362  
Confidential              
  
49 
Version 11.0 / February 18, 2022   7.3 Guidelines for Evaluation  of Measurable Disease  
7.3.1 Measurement Methods  
• All measurements should be recorded in metric notation (i.e., d e c i m a l  f r a c t i o n s  o f  
centimeters) using a ruler or calipers.  
• The same method of assessment and the same technique must be us ed to characterize each 
identified and reported lesi on at baseline and during follow-up .   
• Imaging-based evaluation is pre ferred to evaluation by [CONTACT_757033] a 
treatment.  
• All measurements will be made  based on RECIST guideline version  1.144  
7.3.2 Acceptable Imaging Modalities for Measurable Disease  
• CT chest, abdomen and pelvis wit h IV contrast is the preferred modality to assess the 
presence of visible disease in study patients and then to follo w their response to 
chemotherapy. When CT cannot be used, MRI chest, abdomen and pe lvis is acceptable.  
If there is a lesion that is un certain as to whether it is dise ase or not, PET-CT can be used 
to make this determination per th e investigator’s  discretion.  
• Conventional CT: This guideline h as defined measurability of le sions on CT scan based 
on the assumption that CT slice thickness is [ADDRESS_1036375] scans should be the  default mode of assessing fo r visible disease in all 
patients.  
• Clinical Lesions: Clinical lesions will only be considered meas urable when they are 
superficial (e.g., skin nodules and palpable lymph nodes) and > 10 mm diameter as 
assessed using calipers (e.g., skin nodules). In the case of sk in lesions, documentation by 
[CONTACT_6775], including a rul er to estimate the size of th e lesion, is recommended.  
• Ultrasound (US): Ultrasound is not  useful in assessment of lesi on size and should not be 
used as a method of measurement. Ultrasound examinations cannot  be reproduced in their 
entirety for independent review at a later date and, because th ey are operator dependent, 
it cannot be guaranteed that the same technique and measurement s will be taken from one 
assessment to the next. If new lesions are identified by [CONTACT_757034], confirmation by [CONTACT_12154]. If there is concer n about radiation exposure 
at CT, MRI may be used instead of  CT in selected instances.  
SKCCC J12138 
IND 117362  
Confidential              
  
50 
Version 11.0 / February 18, [ADDRESS_1036376]  
Response and progression will be evaluated in this study using the new international criteria 
proposed by [CONTACT_676067] T umors (RECIST) guidelines 
(version 1.1)44.  Radiologists are our institution will be interpreting the fi lms and the principle 
investigator will be determini ng the type of response or progre ssion using the RECIST criteria.  
[IP_ADDRESS] Target Lesions  
• All measurable lesions (as defined in Section 7.2) up to a maxi mum of 2 lesions per organ 
and 5 lesions in total, represen tative of all involved organs, should be identified as target 
lesions and recorded and measured at baseline. If the protocol specified studies are 
performed, and there are fewer than 5 lesions identified (as th ere often will be), there is 
no reason to perform additional studies beyond those specified in the protocol to discover 
new lesions.  
• Target lesions should be selected on the basis of their size (l esions with the longest 
diameter), be representative of  all involved organs, but in add ition should be those that 
lend themselves to reproducible repeated measurements. It may b e the case that, on 
occasion, the largest lesion does not lend itself to reproducib le measurement in which 
circumstance the next largest lesion which can be measured repr oducibly should be 
selected.  
• Baseline sum of Diameters (BSD): A sum of the diameters (longes t for non-nodal lesions, 
short axis for nodal lesions) for all target lesions will be ca lculated and reported as the 
baseline sum of diameters. If lymph nodes are to be included in  the sum, then only the 
short axis is added into the sum. The BSD will be used as refer ence to further characterize 
any objective tumor response in the measurable dimension of the  disease.  
[IP_ADDRESS] Non-Target Lesions  
All other lesions (or sites of disease) should be identified as  non-target lesions a nd should also be 
recorded at baseline. Measuremen ts are not required, and these lesions should be followed in 
accord with Section [IP_ADDRESS].   
7.3.[ADDRESS_1036377] be followed on reevaluatio n. Specifically, a change in objective 
status to either a PR or CR ca nnot be done without rechecking a ll identified sites (i.e., target and 
non-target lesions) of pr e-existing disease.    
SKCCC J12138 
IND 117362  
Confidential              
  
51 
Version 11.0 / February 18, 2022   [IP_ADDRESS] Evaluation of Target Lesions  
• Complete Response (CR): Disappearance of all target lesions and normalization of tumor 
biomarkers (CA 19-9) . Any pathological lymph nodes (whether target or non-target) m ust 
have reduction in short axis to < 1 cm.  
• Partial Response (PR): At least a 30% decrease in the sum of th e diameters of target lesions 
taking as reference the BSD.  
• Progression (PD): At least a 20% i ncrease in the sum of diamete rs of target lesions taking 
as reference the smallest sum of diameters recorded on study (t his includes the baseline 
sum if that is the smallest on study) or the appearance of one or more new lesions. In 
addition to the relative increase of 20%, the sum must also dem onstrate an absolute 
increase of at least 5 mm.  
• Stable Disease (SD): Neither sufficient shrinkage to qualify fo r PR nor sufficient increase 
to qualify for PD taking as refer ences the smallest sum of diam eters while on study.  
[IP_ADDRESS] Evaluation of Non-Target Lesions  
• Complete Response (CR): Disappear ance of all non-target lesions  and normalization of 
tumor biomarker level. All lymph nodes must be non-pathological  in size (< 1 cm short 
axis)  
• Non-CR/Non-PD: Persistence of one  or more non-target lesions an d/or maintenance of 
tumor biomarker level above the normal limits.   
• Progression (PD): Appearance of one or more new lesions. Unequi vocal progression of 
existing non-target lesions. U nequivocal progression should not  normally trump target 
lesion status. It must be representative of overall disease sta tus change, not a single lesion 
increase.  
• NOTE: Although a clear progression  of “non-target” lesions only  is exceptional, in such 
circumstances, the opi[INVESTIGATOR_756995], and the progression status 
will be confirmed at a later ti me by [CONTACT_177108] a revie w panel.  
 
7.3.[ADDRESS_1036378]’s status on 
target lesions, non-target lesions , and new disease as defined in the following tables (Table 
[IP_ADDRESS], [IP_ADDRESS])  
 
Table [IP_ADDRESS]  For Subjects with Measurable Di sease (i.e., Target Disease):   
SKCCC J12138 
IND 117362  
Confidential              
  
52 
Version 11.0 / February 18, 2022    
Target 
Lesions  Non-Target 
Lesions*  New 
Lesions  CA 19-9  Overall  
Objective  
Status  
CR  CR  No  Normal (≤ 
ULN)  CR  
CR  Non-CR/Non-
PD/not evaluated  No  Normal  PR  
PR  Non-CR/Non-
PD/not evaluated  No  Any value  PR  
SD  Non-CR/Non-
PD/not evaluated  No  Any value  SD  
PD  Any  Yes or No  Any value  PD  
Any  PD  Yes or No  Any value  PD  
Any  Any  Yes  Any value  PD  
  * ‘Non-CR/non-PD’ is preferred over ‘stable disease’ for non-
target disease since SD is incr easingly used as an endpoint for  
assessment of efficacy in some trials so to assign this categor y 
when no lesions can be meas ured is not advised.  
  
Table [IP_ADDRESS]  For Subjects with Non-Measurable  Disease (i.e., Non-Target Dis ease):  
Non-Target 
Lesions  New Lesions  CA 19-9  Overall Objective 
Status  
CR  No  Normal  CR  
Non-CR/non-PD  No  Any value  Non-CR/non-PD*  
Not all evaluated  No  A ny value  not evaluated  
Unequivocal PD  Yes or No  Any value  PD  
Any  Yes  Any value  PD  
  * ‘Non-CR/non-PD’ is preferred over ‘stable disease’ for 
non-target disease since SD is increasingly used as an 
endpoint for assessment of efficacy in some trials so to 
assign this category when no lesions can be measured is 
not advised.  
 
SKCCC J12138 
IND 117362  
Confidential              
  
53 
Version 11.0 / February 18, 2022   [IP_ADDRESS] Residual Disease  
In some circumstances it may be difficult to distinguish residu al disease from normal tissue. When 
the evaluation of complete res ponse depends upon this determina tion, it is recommended that the 
residual lesion be investigated ( fine needle aspi[INVESTIGATOR_337]/biopsy) b efore confirming the complete 
response status.  
[IP_ADDRESS] Symptomatic Deterioration  
Subjects with global deteriorat ion of health status requiring d iscontinuation of treatment without 
objective evidence of disease progression at that time, and not  either related to study treatment or 
other medical conditions, should be reported as PD due to “symp tomatic deterioration.”  
Examples of symptomatic deterioration include:   
• Weight loss >10% of body weight.  
• Worsening of tumor-related symptoms.  
• Decline in performance status  of >[ADDRESS_1036379] patients who will be responders 
versus non-responders and identify predictive signatures of pos sible recurrence and benefits of 
CC-486 therapy.  
8.1 Plasma/Serum Samples  
Blood for correlative studies will be drawn from all subjects i n the study at screening and on Cycle 
[ADDRESS_1036380] cycle (Cycle  4, 7, 10, etc.) th ereafter. Blood 
for correlative studies will also be drawn from all patients at  disease progression during the initial 
CC-486/observation phase. The blood samples will be used to ass ess the methylation status of 
free tumor DNA circulating in the blood.  Both global and candi date gene methylation patterns 
SKCCC J12138 
IND 117362  
Confidential              
  
54 
Version 11.0 / February 18, 2022   will be evaluated in plasma samples.  Some of the potential can didate genes include: TMS1, 
ARH1, hMLHI.     
 
Quantitative analysis using real-time Methylation-specific PCR (MSP) will be used to detect the 
presence of methylated alleles for specific genes.  Genes found  to be methylated in pretreatment 
samples will be monitored for ch anges during and after treatmen t using real-time MSP.  DNA 
will first be extracted from plasma using standard phenol chlor oform extraction.  The DNA will 
then be analyzed for changes in DNA methylation at specific gen e promoters that include TMS1, 
ARH1, hMLHI .  PCR primers for these have been described and are in frequen t use in the 
Azad/Yarchoan lab.  This strategy of real-time MSP has recently  shown promising results in an 
ongoing trial in metastatic lung cancer with combination epi[INVESTIGATOR_756996] 5-
azacitidine and the HDAC inhibitor, entinostat.  
 
We will also do methylation status analysis on samples using Me thylation-on-Beads (MOB), a 
novel nano-enabled methylation based technology.  This assay ha s shown great promise as a tool 
for surveillance of responses to epi[INVESTIGATOR_756997].  The 
utility of the nano-enabled platform will also be explored in t he ongoing correlative studies since 
this may provide a more sensitiv e assay for detection of respon se to epi[INVESTIGATOR_756998].  
8.2 Tumor Biopsies  
Tumor biopsies will be attempted on all subjects at the time of  visible disease recurrence.  We 
will also consent subjects to obtain paraffin-embedded blocks o f their original resected pancreatic 
tumor.  Methylation status will b e assessed on these samples to  correlate with the data received 
from the plasma analysis.  All new biopsy specimens will be sto red as fresh tissue at ≤ -70°C for 
extraction of DNA and RNA.  
 
All biopsy specimens will undergo tumor methylation analysis wi th MSP for select candidate 
genes ( TMS1 , ARH1 , etc) as described above.  Evaluation of expression of genes t hat become 
demethylated post-treatment will be performed using quantitativ e real-time PCR, whenever 
possible.  Where sufficient tissue is obtained, samples will al so be studied using an Infinium 
Methylation Assay that surveys  genome-wide DNA methylation prof iles (such as the Illumina  
HumanMethylation27 BeadChip or th e newer Infinium HumanMethylat ion450 BeadChip).  This 
technology examines approximately 27,500 CpGs in 14,500 regions , including 12,833 well-
annotated genes described in the NCBI CCDS database, 144 methyl ation hotspots in cancer genes, 
982 cancer related targets, and 110 microRNA promoters.  Result s are analyzed using BeadStudio 
software that allows for data analysis and integration of methy lome data with mRNA or miRNA 
expression array studies.  In regions of cancer hotspots, there  are 7 CpGs studied on average per 
SKCCC J12138 
IND 117362  
Confidential              
  
55 
Version 11.0 / February 18, 2022   gene.  As little as 500ng of input DNA is required for the Bead Chip, which allows for investigation 
of samples collected by [CONTACT_450630].  We will  investigate if the Illumina 
Infinium chip can be used to defi ne epi[INVESTIGATOR_756999]-responders 
to oral epi[INVESTIGATOR_278211].  
8.2.1 Specimen Collection and Handling  
[IP_ADDRESS] Blood  
Blood samples for methylation anal ysis will be collected from a ll participants in EDTA BD 
Vacutainer cell preparation tube s (purple tubes, Becton Dickins on, Franklin Lakes, NJ).  These 
tubes are designed to separate plasma and mononuclear cells fro m whole blood.  Forty to sixty 
mL of blood will be collected from each subject during each col lection as per Section 2, Schedule 
of Study Assessment.  For samples  drawn at Johns Hopkins, tubes  will be transpo rted on ice and 
processed within [ADDRESS_1036381]. Azad/ Yarchoan’s laboratory.   Blood collected at other sites 
will follow the process for shippi[INVESTIGATOR_757000] H ospi[INVESTIGATOR_757001]. All blood not used for correla tive analyses will be stored for 
future use if new biomarkers a re developed that may better pred ict recurrence. 
[IP_ADDRESS] Archival Tissue  
Patients will be consented in ord er for us to obtain paraffin-e mbedded blocks and slides of their 
original resected tumor. This will enable us to perform methyla tion analysis on the primary tumor 
and compare this to the tumors at the time of recurrence to det ermine if treatment with CC-[ADDRESS_1036382] ained for H&E (Hematoxylin and 
Eosin) for confirmation of the p resence of tumor tissue; then, up to 20 serially cut slides should 
follow. Slides should be 10 microns in thickness and placed in tubes; alternatively, sections may 
be mounted on charged or silanted slides without coverslips. Th e H&E stained and all unstained 
slides will be submitted.   
[IP_ADDRESS] Tumor Biopsies  
At the time of recurrence, there must be an attempt to obtain t umor samples by [CONTACT_757035].  A maximum of 8 core biopsies (or  fine needle aspi[INVESTIGATOR_757002]) will be obtained from each subject.  The asp irates will be used to prepare air 
dried cytologic smears and frozen samples.  The first pass will  be used for on-site examination of 
the material, to determine prese nce and quality of lesional tis sue.  The remaining biopsy 
specimens will be flash frozen in liquid nitrogen and then stor ed as fresh tissue at ≤ -70°C for 
extraction of DNA and RNA.  The biopsy specimens will be stored  and evaluated in [CONTACT_594650]/ 
Yarchoan’s laboratory.    
 
SKCCC J12138 
IND 117362  
Confidential              
  
56 
Version 11.0 / February 18, 2022   [IP_ADDRESS] Subject Anonymity  
A unique subject identifier will be assigned to each subject an d will be used to identify tumor 
biopsies and blood samples.  The protocol scientific investigat or(s) handling the samples will be 
blinded as to the subject iden tification, subject data and outc ome.  
9 Protocol Amendments/Deviations  
9.[ADDRESS_1036383] be agreed to by [CONTACT_757036]. Amendments should only be submitted to IRB/EC after co nsideration of Celgene 
review. Written verification of IRB/EC approval will be obtaine d before any amendment is 
implemented.    
9.[ADDRESS_1036384] (for w hom the deviation from protoco l was effected) is to continue in 
the study.  The subject’s medical r ecords will completely descr ibe the deviation from the protocol 
and state the reasons for such deviation.  In addition, the Inv estigator will notify the IRB/EC in 
writing of such deviation from protocol. Non-emergency minor de viations from the protocol will 
be permitted with approval of the Principal Investigator.   
 
External sites will submit a ma ster deviation log to the Coordi nating Center monthly by [CONTACT_6968], at 
 
10 Data Management  
10.1 Data Collection  
Data will be collected and reported on either paper case report  forms (CRF) or through an internal 
data monitoring system, which will be determined prior to the s tart of the study.  
10.2 Analyses and Reporting  
Data Submission  
Data and/or completed case report forms must be transmitted ele ctronically using the study web 
based system provided by [CONTACT_757037] H opkins (CRMS). Data will be com pleted and submitted weekly 
for cycle 1 and monthly for each subsequent cycle. Case report forms will be provided to 
participating sites by [CONTACT_5081].   
  

SKCCC J12138 
IND 117362  
Confidential              
  
57 
Version 11.0 / February 18, 2022   Data will be analyzed and reported after the trial has complete d accrual. All subsequent data 
collected will be analyzed and r eported in a follow-up clinical  report.   
  
10.3 Clinical Trial Monitoring  
The SKCCC Compliance Monitoring Program will provide external m onitoring for JHU-
affiliated sites in accordance with SKCCC DSMP (Version 6.0, 02 /21/2019). The SMC 
Subcommittee will determine the level of patient safety risk an d level/frequency of monitoring. 
Eligibility for all sites will be monitored by [CONTACT_757038]. The IND Sponsor and PI [INVESTIGATOR_757003] e progress of the trial, includ ing review and confirmation of all 
safety/treatment-related outcomes, response assessments, safety  reports and/or any related source 
documentation. Additional data and safety monitoring oversight will also be performed by [CONTACT_757039] (SMC - as defined in the DSMP ). External monitoring 
will occur according to t he following guidelines:  
  
Johns Hopkins SKCCC: The protocol will be monitored externally b y  t h e  S K C C C  C R O  i n  
accordance with SKCCC guidelines. Trial monitoring and reportin g will be done through the 
Safety Monitoring Committee (SMC) at SKCCC.   
  
Participating site(s): The protocol will be monitored by [CONTACT_757040]. A report of 
the reviews will be submitted to the Johns Hopkins principal in vestigator and SKCCC CRO.  
  
Authorized representatives of th e Coordinating Center may visit  t h e  s a t e l l i t e  s i t e s  t o  p e r f o r m  
audits or inspections, including source data verification. The purpose of these audits or inspections 
is to systematically and independently examine all trial-relate d activities and documents to 
determine whether these activities were conducted and data were  recorded, analyzed, and 
accurately reported according to the protocol, Good Clinical Pr actice (GCP), and any applicable 
regulatory requirements.  
  
[CONTACT_594650] will be holding the IND for this study.  She will comp ly with all regulated reporting 
requirements to the FDA.  
10.4 Investigator Responsibilities  
Investigator responsibilities are set out in the ICH guideline for Good Clinical Practice (GCP) and 
in the US Code of Fed eral Regulations.  
 
Investigators must enter study da ta onto CRFs or other data col lection system.  The Investigator 
will permit study-related audits by [CONTACT_757041], IRB/EC review, and regulatory 
SKCCC J12138 
IND 117362  
Confidential              
  
58 
Version 11.0 / February 18, 2022   inspection(s) (e.g., FDA, EMEA, TPP), providing direct access t o the facilities where the study 
took place, to source documents, t o CRFs, and to all other stud y documents.  
 
The Investigator, or a designate d member of the Investigator’s staff, must be available at some 
time during audits to review data and resolve any queries and t o allow direct access to the subject’s 
records (e.g., medical records, o ffice charts, hospi[INVESTIGATOR_1332],  and study related charts) for source 
data verification.  The data collection must be completed prior  to each visit and be made available 
to the Celgene representative so that the accuracy and complete ness may be checked.  
10.5 Safety Meetings  
Monthly teleconferences will be scheduled to include the PI/Spo nsor, site Princip al Investigators, 
Coordinating Center representati ves, Site representatives and C elgene representatives (as 
appropriate). During these meeti ngs, the Investigators shall pr ovide the Coordinating Center with 
study progress updates.  The Inve stigators will provide a summa ry of key points from the weekly 
meetings with a focus on safety o f the protocol participants, e nrollment status, and progress of 
data for objectives.  In addition, Celgene will provide safety and applicable program updates to 
the Sponsor.  
 
11 Biostatistical Analysis  
11.1 Study Design/Endpoints  
This trial is a phase II trial with the primary endpoint to dem onstrate an increase in progression 
free survival in the CC-486 arm (Arm A) as compared to the obse rvational arm (Arm B).   
Secondary endpoints include determining the response rate to ch emotherapy, overall survival, and 
hypomethylation seen in the CC-486 a rm as compared to the obser vational arm.   
11.2 Study Populations  
11.2.1 Efficacy Evaluable Population  
The primary comparisons will include all randomized patients ac cording to the assigned treatment 
groups (i.e. ‘as randomized’). Secondary sensitivity analyses w ill examine the subset of patients 
receiving at least [ADDRESS_1036385] s with any evaluable methylation 
results including plasma  and/or tumor biopsies.  
 
SKCCC J12138 
IND 117362  
Confidential              
  
59 
Version 11.0 / February 18, [ADDRESS_1036386].  
 
Time to event outcomes, including the primary endpoint progress ion free survival and overall 
survival, will be summarized using Kaplan-Meier estimates of th e survival function.  From these 
estimates, median time to event and one-year survival proportio ns with 95% confidence intervals 
will be extracted.  Cox proportional hazards models will be use d to compare the two treatment 
arms and to evaluate and adjust for potential prognostic factor s (e.g. nodal status, microscopic 
margins, increase in CA19-9, therapy).  The number and type of responses to chemotherapy will 
be tabulated for each group.  Logistic regression will be used to compare the response rate between 
the groups and to identify risk factors associated with respons e. Results will be considered 
statistically significant for p-values < 0.05.  
11.3.[ADDRESS_1036387] sample size a nd are exploratory in nature only 
and are meant for hypothesis generation for further studies.  S ummary statistics (e.g. means, 
standard errors) and plots will b e used to describe the pharmac odynamic endpoints at each time 
point (resection and relapse) as well as the change over time.  T-tests will be used to assess the 
differences in the change in pharmacodynamic outcomes between t hose with and without CC486 
exposure.  These changes may also be quantified as a binary var iable (response vs. no response) 
in which case the comparisons will be made using Fisher’s exact  test.  Modeling approaches, 
which allow for the assessment of multiple variables, will also  be considered for both the 
continuous outcomes (linear regression) and binary outcomes (lo gistic regression).  A generalized 
estimating equation approach will also be considered to allevia te the impact of missing data on 
the inference.   
11.3.3 Quality of life analysis  
Quality of life will be assessed at screening and/or cycle 1 da y 1 and then every 3 cycles thereafter 
(cycles 4, 7 and 10) using the F unctional Assessment of Chronic  Illness Therapy Hepatobiliary 
Cancer (FACIT-Hep) questionnaire .  The hepatobiliary, general f unction, and subscale scores will 
SKCCC J12138 
IND 117362  
Confidential              
  
60 
Version 11.0 / February 18, 2022   be will be graded according to the guidelines provided at http: //www.facit.org.  Summary statistics 
(e.g. means, medians, ranges) a nd graphical tech niques (e.g. bo x-plots over time) will be used to 
summarize the patterns of scores over time and assess whether o r not transformations are 
necessary.  Comparisons of the differences in the change in sco res over time between treatment 
groups will be performed using generalize estimating equations (GEE).  Sensitivity analyses will 
be performed to assess the impact of missing data including bes t and worst case single imputation, 
multiple imputation.  One issue when assessing quality of life is how to handle scores for 
individuals who have died.  Some questionnaires (e.g. Stroke mo dified Rankin Score) include 
death as a value on the scale; however, this is not the case fo r the FACIT questionnaires.  We will 
assess the impact of missing data due to death by [CONTACT_757042].  
11.3.4 Sample Size   
The anecdotal time to progression without treatment is approxim ately 4 to 6 months.  A feasible 
goal of 60 patients (30 in each arm) will provide 80% power to identify a 64% improvement in 
the median PFS from the null rate of 6 months assuming a one-si ded type 1 error rate of 0.20, 24 
months of accrual and a minimum of 12 months of follow-up while  allowing for 10% loss to 
follow-up (protocol accruing for  6 months at the time of submis sion.  
    
1-sided Type I error rate   Detectable HR (N = 60)  
0.05  2.12  
0.10  1.89  
0.15  1.74  
0.20  1.64  
  
11.3.5 Safety Monitoring  
Although the dose level is below the maximally tolerated dose, we will monitory the rates of grade 
3/[ADDRESS_1036388] to observe grade 3/4 toxicities 
in 15% of patients.  The goal is to ensure that the percentage of grade 3/4 toxicities remains below 
30%.  A Bayesian stoppi[INVESTIGATOR_757004].  The pr ior was chosen t o be a Beta (1, 
4), representing a 20% toxicity rate, which is at the high end of our expected value.  The guidelines 
will recommend that the therapy be re-evaluated if the posterio r probability of t oxicity exceeding 
30% is greater than 65%.  Tab le [IP_ADDRESS] below summarizes the s toppi[INVESTIGATOR_757005].   
 
Table [IP_ADDRESS] 
SKCCC J12138 
IND 117362  
Confidential              
  
61 
Version 11.0 / February 18, 2022    
Cohort size Observed number 
of toxicities that 
trigger re-evaluation  
6-9  4  
10-12  5  
13-15  6  
16-18  7  
19-21  8  
22-24  9  
25-27  10  
28-31  11  
 
The probability of triggering the stoppi[INVESTIGATOR_757006] a range of underlying 
toxicity rates based upon simulations with 5000 replicates (Tab le [IP_ADDRESS] below).  In the expected 
range of toxicity, the probabil ity of stoppi[INVESTIGATOR_757007] t han 4.8%.  
Table [IP_ADDRESS] 
 
True underlying  
toxicity rate Probability of triggering  
stoppi[INVESTIGATOR_757005] 
10%  1.2% 
15%  4.8% 
20%  14.1% 
25%  32.2% 
30%  54.1% 
40%  89.6% 
50%  99.1% 
 
11.3.6 Futility Analysis  
An interim futility analysis will be performed once 50% of the expected progressions have 
occurred.   The conditional power will be calculated for the fo llowing three scenarios for the 
unobserved data: 
 Null hypothesis: Assumes no difference between the two treatmen t arms, i.e. the median 
PFS in both groups is 6 months. 
SKCCC J12138 
IND 117362  
Confidential              
  
62 
Version 11.0 / February 18, 2022    Alternative hypothesis: Assumes that the originally hypothesize d rates (6 months vs 9.84 
months) will be observed. 
 Current pattern: Assumes that the PFS observed for each group i n the initial cohort will 
be observed for the remaining patients. 
 
The decision to stop or continue will be based upon the current ly observed pattern with the null 
and alternative hypothesis patterns providing an estimate of th e range of possible values.  Since 
the cost of continuing (in terms of safety, resources and monet ary cost) is low relative to the 
information to be gained, a low t hreshold for continuing was se lected.  We will stop the trial and 
conclude futility if the conditional power is 30% or less.  Oth erwise, the trial will continue.  No 
interim efficacy analysis is planned due to the high cost of ty pe I error spending associated with 
an interim efficacy analysis. 
 
[ADDRESS_1036389]/ Ethics Committee approval  
The protocol for this study has been designed in accordance wit h the general ethical principles 
outlined in the Declaration of Helsinki.  The review of this pr otocol by [CONTACT_1201]/EC and the 
performance of all aspects of the study, including the methods used for obtaining informed 
consent, must also be in accordance with principles enunciated in the declaration, as well as ICH 
Guidelines, Title 21 of the Code of Federal Regulations (CFR), Part 50 Protection of Human 
Subjects and Part 56 Institu tional Review Boards.  
 
The Investigator will be respons ible for preparing documents fo r submission to the relevant 
IRB/EC and obtaining written a pproval for thi s study.  The appr oval will be obtained prior to the 
initiation of the study.  
 
The approval for both the protocol and informed consent must sp ecify the date of approval, 
protocol number and version, or amendment number. Any amendment s to the protocol after 
receipt of IRB/EC approval must be submitted by [CONTACT_12244] r to the IRB/EC for approval.  
The Investigator is also responsible for notifying the IRB/EC o f any serious deviations from the 
protocol, or anything else that m ay involve added risk to subje cts.  
 
Any advertisements used to rec ruit subjects for the study must be reviewed and approved by [CONTACT_5040]/EC prior to use.  
SKCCC J12138 
IND 117362  
Confidential              
  
63 
Version 11.0 / February 18, [ADDRESS_1036390] or h is/her designee prior to any study 
related procedures as per GCPs a s set forth in the CFR and ICH guidelines.  
 
Documentation that informed cons ent occurred prior to the subje ct’s entry into the study and the 
informed consent process should be recorded in the subject’s so urce documents.  The original 
consent form signed and dated by [CONTACT_271200]’s entry into the study mu st be maintained in the Invest igator’s study files.  
12.[ADDRESS_1036391]’s r ight to protection against invas ion of privacy.  I n compliance with 
[LOCATION_002] federal regulations , Celgene requires the Investi gator to permit representatives of 
Celgene Corporation and, when necessary, representatives of the  FDA or other regulatory 
authorities to review and/or c opy any medical records relevant to the study in accordance with 
local laws.  
 
Should direct access to medical records require a waiver or aut horization separate from the 
subject’s statement of informed consent, it is the responsibili ty of the Investigator to obtain such 
permission in writing from the appropriate individual.  
12.[ADDRESS_1036392] of the study 
and the distribution of the protocol therapy, that is copi[INVESTIGATOR_757008] (original 
documents, data, and records [e.g., hospi[INVESTIGATOR_1097]; clinical and office charts; laboratory notes; 
memoranda; subject’s diaries or evaluation checklists; SAE repo rts, pharmacy dispensing records; 
recorded data from automated instruments; copi[INVESTIGATOR_757009]; microfiches; photographic negatives, mic rofilm, or magnetic media; x-
rays; subject files; and records kept at the pharmacy, at the l aboratories, and at medico-technical 
departments involved in the clin ical study; documents regarding  subject treatment and drug 
accountability; original signed in formed consents, etc.]) be re tained by [CONTACT_757043]  (generally [ADDRESS_1036393] marketing approval).  The Investigator agrees 
to adhere to the document/record s retention proc edures by [CONTACT_757044].  
 
12.[ADDRESS_1036394] the ri ght to discontinue this study at any 
time for reasonable medical or administrative reasons.  Possibl e reasons for termination of the 
study could be but are not limited to:  
SKCCC J12138 
IND 117362  
Confidential              
  
64 
Version 11.0 / February 18, 2022   • Unsatisfactory enrollment wit h respect to quantity or quality.  
• Inaccurate or incomplete data collection.  
• Falsification of records.  
• Failure to adhere to  the study protocol.  
Any possible premature discontinuation would be documented adeq uately with reasons being 
stated, and information would have to be issued according to lo cal requirements (e.g., IRB/EC, 
regulatory authorities, etc.).  
 
[ADDRESS_1036395] E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating 
socioeconomic and racial disparities on premature cancer deaths . CA Cancer J Clin  2011; 
61(4): 212-36.  
2. Bunger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers  for improved 
diagnostic of pancreatic can cer: a current overview. J Cancer Res Clin Oncol  2011; 
137(3): 375-89.  
3. Sharma C, Eltawil KM, Renfrew PD , Walsh MJ, Molinari M. Advance s in diagnosis, 
treatment and palliation of p ancreatic carcinoma: 1990-2010. World J Gastroenterol  
2011; 17(7): 867-97.  
4. Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine  a l o n e  v e r s u s  
gemcitabine-based chemoradiothe rapy after curative resection fo r pancreatic cancer: a 
randomized EORTC-[ZIP_CODE]-[ZIP_CODE]/FFCD- 9203/GERCOR phase II study. J Clin Oncol  
2010; 28(29): 4450-6.  
5. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreat ic cancer. Lancet  
2011; 378(9791): 607-20.  
6. Edge SB, Compton CC. The America n Joint Committ ee on Cancer: th e 7th edition of the 
AJCC cancer staging manual a nd the future of TNM. Ann Surg Oncol  2010; 17(6): 1471-
4.  
7. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging no de-negative pancreas 
cancer: a potential quality measure. Arch Surg  2007; 142(8): 767-23; discussion 73-4.  
8. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance  of lymph node ratio 
following pancreaticoduodenectomy for pancreatic cancer. Surgery  2007; 141(5): 610-8.  
9. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy  with or without distal 
gastrectomy and extended retroperitoneal lymphadenectomy for pe riampullary 
adenocarcinoma, part 2: randomi zed controlled trial evaluating survival, morbidity, and 
mortality. Ann Surg  2002; 236(3): 355-66; discussion 66-8.  
SKCCC J12138 
IND 117362  
Confidential              
  
65 
Version 11.0 / February 18, 2022   10. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduod enectomies for 
pancreatic cancer: A singl e-institution experience. J Gastrointest Surg  2006; 10(9): 1199-
210; discussion 210-1.  
11. Takahashi H, Ohigashi H, Ishikaw a O, et al. Perineural invasion  and lymph node 
involvement as indicators of surg ical outcome and pattern of re currence in the setting of 
preoperative gemcitabine-based che moradiation therapy for resec table pancreatic cancer. 
Ann Surg  2012; 255(1): 95-102.  
12. Katz MH, Wang H, Fleming JB, et al. Long-term survival after mu ltidisciplinary 
management of resected pancreatic adenocarcinoma. Ann Surg Oncol  2009; 16(4): 836-
47.  
13. Showalter TN, Winter KA, Berger AC, et al. The influence of tot al nodes examined, 
number of positive nodes, and lymph node ratio on survival afte r surgical resection and 
adjuvant chemoradiation for pancreatic cancer: a secondary anal ysis of RTOG 9704. Int J 
Radiat Oncol Biol Phys  2011; 81(5): 1328-35.  
14. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following 
curative resection for pancreatic ductal adenocarcinoma. A syst ematic review of the 
literature. JOP 2008; 9(2): 99-132.  
15. Schmidt CM, Glant J, Winter JM , et al. Total pancreatectomy (R0  resection) improves  
survival over subtotal pancreatectomy in isolated neck margin p ositive pancreatic 
adenocarcinoma. Surgery  2007; 142(4): 572-8; discussion 8-80.  
16. Tseng JF, Raut CP, Lee JE, et a l. Pancreaticoduodenectomy with vascular resection: 
margin status and survival duration. J Gastrointest Surg  2004; 8(8): 935-49; discussion 
49-50.  
17. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C, 
Warshaw AL. Perioperative CA19-[ADDRESS_1036396] stage and s urvival in patients with 
resectable pancreatic adenocarcinoma. J Clin Oncol  2006; 24(18): 2897-902.  
18. Berger AC, Garcia M, Jr., Hoffma n JP, et al. Postresection CA 1 9-9 predicts overall 
survival in patients with pancreatic cancer treated with adjuva nt chemoradiation: a 
prospective valid ation by [CONTACT_111527] 9704. J Clin Oncol  2008; 26(36): 5918-22.  
19. Lomberk GA. Epi[INVESTIGATOR_757010] p ancreatic cancer. J 
Gastrointest Cancer  2011; 42(2): 93-9.  
20. McCabe MT, Brandes JC, Vertino PM . Cancer DNA methylation: mole cular mechanisms 
and clinical implications. Clin Cancer Res  2009; 15(12): 3927-37.  
21. Grzenda A, Ordog T, Urrutia R. Polycomb and the emerging epi[INVESTIGATOR_757011]. J Gastrointest Cancer  2011; 42(2): 100-11.  
22. Sherr CJ. Principles of tumor suppression. Cell 2004; 116(2): 235-46.  
23. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic car cinogenesis. 
Pancreatology  2008; 8(2): 110-25.  
SKCCC J12138 
IND 117362  
Confidential              
  
66 
Version 11.0 / February 18, 2022   24. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res  2009; 15(12): 
3938-46.  
25. Silverman LR, Demakos EP, Peterson BL, et al. Randomized contro lled trial of azacitidine 
in patients with the myelodyspl astic syndrome: a study of the c ancer and leukemia group 
B. J Clin Oncol  2002; 20(10): 2429-40.  
26. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine pr olongs overall survival 
compared with conventional care regimens in elderly patients wi th low bone marrow blast 
count acute myeloid leukemia. J Clin Oncol  2010; 28(4): 562-9.  
27. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in 
elderly patients with intermedia te- or high-risk myelodysplasti c syndrome (MDS) 
ineligible for intensive chemotherapy: final results of the ran domized phase III study of 
the European Organisation for Research and Treatment of Cancer Leukemia Group and 
the German MDS Study Group. J Clin Oncol  2011; 29(15): 1987-96.  
28. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of az acitidine compared with 
that of conventional care regimens in the treatment of higher-r isk myelodysplastic 
syndromes: a randomised, open-label, phase III study. Lancet Oncol  2009; 10(3): 223-32.  
29. Garcia-Manero G. Myelodysplasti c syndromes: 2011 update on diag nosis, 
riskstratification, and management. Am J Hematol  2011; 86(6): 490-8.  
30. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pi[INVESTIGATOR_757012]. Leukemia  2008; 22(9): 1680-4.  
31. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral  azacitidine in 
myelodysplastic syndromes, chronic myelomonocytic leukemia, and  a c u t e  m y e l o i d  
leukemia. J Clin Oncol  2011; 29(18): 2521-7.  
32. Hui AB, Lo KW, Kwong J, et al. Epi[INVESTIGATOR_757013]1  gene in 
nasopharyngeal carcinoma. Mol Carcinog  2003; 38(4): 170-8.  
33. Chan AS, Tsui WY, Chen X, et al. Downregulation of ID4 by [CONTACT_757045]. Oncogene  2003; 22(44): 6946-53.  
34. Li M, Zhao ZW. Clinical implications of mismatched repair gene promoter methylation 
in pancreatic cancer. Med Oncol  2011.  
35. Yang H, Lu X, Qian J, et al. Imprinted tumor suppressor gene AR HI induces apoptosis 
correlated with changes in DNA methylation in pancreatic cancer  cells. Mol Med Report  
2010; 3(4): 581-7.  
36. Kuroki T, Tajima Y, Kanematsu T. Role of hypermethylation on ca rcinogenesis in the 
pancreas. Surg Today  2004; 34(12): 981-6.  
37. Cai HH, Sun YM, Miao Y, et al. Aberrant methylation frequency o f TNFRSF10C 
promoter in pancreatic  cancer cell lines. Hepatobiliary Pancreat Dis Int  2011; 10(1): 95-
100.  
SKCCC J12138 
IND 117362  
Confidential              
  
67 
Version 11.0 / February 18, 2022   38. Ramachandran K, Miller H, Gordian E, Rocha-Lima C, Singal R. Me thylation-mediated 
silencing of TMS1 in pancreatic cancer and its potential contri bution to chemosensitivity. 
Anticancer Res  2010; 30(10): 3919-25.  
39. Gupta S, Pramanik D, Mukherjee R, et al. Molecular determinants  of retinoic acid 
sensitivity in pancreatic cancer. Clin Cancer Res  2012; 18(1): 280-9.  
40. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs 
observation in patients undergoi ng curative-intent resection of  pancreatic cancer: a 
randomized controlled trial. JAMA  2007; 297(3): 267-77.  
41. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial  of chemoradiotherapy 
and chemotherapy after resection of pancreatic cancer. N Engl J Med  2004; 350(12): 1200-
10.  
42. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemothera py with fluorouracil 
plus folinic acid vs gemcitabine  following pancreatic cancer re section: a randomized 
controlled trial. JAMA  2010; 304(10): 1073-81.  
43. Benson AB, 3rd, Ajani JA, Catalano RB, et al. Recommended guide lines for the treatment 
of cancer treatment -induced diarrhea. J Clin Oncol  2004; 22(14): 2918-26.  
44. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response eval uation criteria in solid 
tumours: revised RECIS T guideline (version 1.1). Eur J Cancer  2009; 45(2): 228-47.  
  
  
     
SKCCC J12138 
IND 117362  
Confidential              
  
68 
Version 11.0 / February 18, 2022   14 Appendices  
Appendix A: ECOG Performance Status Scale  
    
SCORE  DESCRIPTION  
0  Fully active, able to carry on all pre-disease performance with out 
restriction.  
1  Restricted in physically strenuous  activity but ambulatory and able 
to carry out work of a light o r sedentary nature, e.g., light h ouse work, 
office work.  
2  Ambulatory and capable of all self-care but unable to carry out  any 
work activities.  Up and about more than 50% of waking hours.  
3  Capable of only limited self-care, confined to bed or chair mor e than 
50% of waking hours.  
4  Completely disabled.  Cannot carry on any self-care.  Totally c onfined 
to bed or chair.  
5  Dead.  
  
  
   
 
 
 
  
  
SKCCC J12138 
IND 117362  
Confidential              
  
69 
Version 11.0 / February 18, 2022   Appendix B: Medication Diary 
J12138  
Medication Diary – CC-486  
Cycle Number __________  
Day 1 Date _____________  
Name_______________________(initials acceptable)               ID_____________________  
  
INSTRUCTIONS:  
1. Complete one form per cycle of therapy.  
2. Take your dose of the study drug days 1 through 21 of each 28 d ay cycle.  CC-486 may be taken 
on an empty stomach or with food.  The tablets should be taken with about 1 cup (240mL) of 
water.  You will take 3 tablets each day (or fewer if you have been dose reduced by [CONTACT_271519]).  You should swallow the tablets whole.  Do not chew , crush, or break the tablets. If a 
dose of CC-[ADDRESS_1036397] them in the Comments section. 
5. Please return the forms to your  physician/research nurse prior to the next cycle of therapy.  
6. On clinic days-please wait to ta ke your medication until after you have been seen b y the RN 
or [CONTACT_757047] time 
was the dose 
taken?  # of tablets   Comments  
1          
2          
3          
4          
5          
6          
7          
8          
9          
10          
11          
SKCCC J12138 
IND 117362  
Confidential              
  
70 
Version 11.0 / February 18, 2022   12          
13          
14          
15          
16          
17          
18          
19          
20          
21          
To be completed by [CONTACT_44498]:  
1. Date protocol treatment was started 
___________________________________________________________                                     
2. Date subject was removed from protocol 
___________________________________________________________  
3. Planned total daily dose 
___________________________________________________________  
4. Total number of pi[INVESTIGATOR_555554] 
___________________________________________________________  
5. Research Study Staff’s Signature: 
___________________________________________________________  
 
Participant’s signature ____________________________________ Da te _______________  
 
 
 
 
 
 
SKCCC J12138 
IND 117362  
Confidential              
  
71 
Version 11.0 / February 18, 2022   Appendix C: Recommendations for Management of Treatment-Induced  Diarrhea (for 
CC-486)  
The following guidelines are based on a publication by [CONTACT_540900].  in the Journal of Clinical 
Oncology43 .  
  
  
  
  
  

SKCCC J12138 
IND 117362  
Confidential              
  
72 
Version 11.0 / February 18, 2022   Appendix D: FACT – Hep (Version 4)  
SKCCC J12138 
IND 117362  
Confidential              
  
73 
Version 11.0 / February 18, 2022     

SKCCC J12138 
IND 117362  
Confidential              
  
74 
Version 11.0 / February 18, 2022     

SKCCC J12138 
IND 117362  
Confidential              
  
75 
Version 11.0 / February 18, 2022      
